Scientific Programme

Wednesday, 24 May 2017

Featured Symposium
12:30 - 16:30
Forum Hall

Post Graduate Course on Liver Transplantation Mastering Viral Infections in Liver Transplantation

Chairs:
Patrizia Burra, Padova, Italy
John O'Grady, London, United Kingdom

Management of HCV patients before transplantation 12:30
Marina Berenguer, Valencia, Spain

Management of HCV patients after transplantation 13:00
Norah Terrault, San Francisco, United States

Consensus Conference on pre and post liver transplant management of HCV 13:30
Norah Terrault, San Francisco, United States

DAAs, renal function and DDIs before and after transplantation 13:40
Michael R. Charlton, Chicago, United States

HCC and HCV in the DAAs era 14:10
Sherrie Bhoori, Milan, Italy

Use of HBsAg, anti-HBcore and anti-HCV positive grafts 14:40
Francesco Paolo Russo, Padova, Italy

Metabolic complications after liver transplantation for viral hepatitis 15:10
Geoffrey McCaughan, Sydney, Australia

Clinical case presentation: “De novo autoimmune hepatitis recurrence after IFN-free antiviral therapy for hepatitis C after liver transplantation” 15:40
Alberto Zanetto, Padova, Italy

Closing remarks 16:00

Others
16:30 - 18:30
North Hall

TEE Workshop

Chairs:
Jeron Zerillo, New York, United States
Dmitri Bezinover, Hershey, United States

Transesophageal echocardiography (TEE)
Sang Kim, New York, United States
Cindy Wang, New York, United States
Scientific Programme

Vanguard Sessions
17:30 - 19:00

Vanguard Moderated Walking Poster Discussions

Chairs:
Michael Ramsay, Texas, United States
John Renz, Chicago, United States
Mark Ghobrial, Houston, United States

P-1  Radiofrequency Ablation as the First Treatment Option for HCC in Transplantable Patients. Is this the Best Strategy?
Gonzalo Sapisochin, Toronto, Canada

P-2  Novel Prognostic Model Based on Tumor Biology and Morphology to Predict HCC Recurrence after Living Donor Liver Transplantation
Prashant Bhangui, Medanta, India

P-3  Achieving Excellent Patient Survival in Combined Liver-Kidney Transplantation (CLKT) by Delayed Kidney Transplant (KT) and Better Quality Kidneys
Burcin Ekser, Indianapolis, United States

P-4  Live Donor Liver Transplant for Adult Acute Liver Failure: Recipient and Donor Outcomes
Ankur Vagadiya, New Delhi, India

P-5  How to Best Predict Acceptable Outcomes after Re-transplantation - Risk Assessment at Different Time-points
Amit Nair, Birmingham, United Kingdom

P-6  The Delivery of Stem Cell Therapy to Extended Criteria Donor Human Livers Using Normothermic Machine Perfusion
Richard Wallace Laing, Birmingham, United Kingdom

P-7  Split Liver Ex-situ Oxygenated Machine Perfusion: A Novel Approach to Organ Preservation and Treatment
Viola Huang, Kaohsiung, Taiwan, Republic of China

P-8  Elastography as a Non-invasive Tool for Assessing Liver Fibrosis in Long-term Survivors of Paediatric Liver Transplantation
Zeng Hao Wong, Singapore, Singapore

P-9  Ledipasvir/Sofosbuvir + Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-world Dataset

P-10  Safety and Efficacy of Interferon-free Antiviral Treatment in Patients with MELD over 20
Carmen Vinaixa, Valencia, Spain

P-11  The Prevalence of Coronary Artery Disease in Liver Transplant Recipients Aged 65 and Older
Christopher Wray, Los Angeles, United States

P-12  Zinc Finger Protein 217 is an Oncogene in Hepatocellular Carcinoma and Promotes Tumor Migration via Epithelial Mesenchymal Transition
Linshi Zhang, Hangzhou, China
The 2017 Joint International Congress of ILTS, ELITA & LICAGE  
May 24 - 27, 2017,  
Prague, Czech Republic

Scientific Programme

Poster Sessions  
17:30 - 19:00

Poster Session 1: Acute Liver Failure

P-13 Neutrophil Gelatinase-associated Lipocalin for the diagnosis of Acute Kidney Injury after Liver Transplantation: A Systematic Review  
Andrew Morozov, London, United Kingdom

P-14 Domino Liver Transplant in Maple Syrup Urine Disease: Technical Details when the First Surgery Is a Living Donor  
Karina Roda, Sao Paulo, Brazil

P-15 Characterisation of the Immune Response in Patients with Drug Induced Liver Injury  
Giacomo Germani, Padua, Italy

P-16 Activation of Autophagy by Everolimus Confers Hepatoprotection against Ischemia-reperfusion Injury  
Kee-Hwan Kim, Uijeongbu, Korea, Republic of

P-17 Mechanical Liver Replacement Therapy in Traumatic and Acute Liver Failure  
John LaMattina, Baltimore, United States

P-18 Etiology and Outcome of Acute Liver Failure in a Single Public Center in Argentina  
Francisco Juan Mattera, Florencio Varela, Argentina

Poster Sessions  
17:30 - 19:00

Poster Session 1: Anesthesia / Critical Care Medicine

P-19 Impact of Inhalational Anesthetics on Liver Regeneration Following Living Donor Hepatectomy  
Kyeo-Woon Jung, Seoul, Korea, Republic of

P-21 The Validity of Central Venous to Arterial Carbon Dioxide Difference to Predict Adequate Fluid Resuscitation during Living Donor Liver Transplantation  
Mohamed Ayashy, Cairo, Egypt

P-22 Perioperative Thrombotic Complications Associated with Pediatric Liver Transplantation. A UNOS Database Evaluation  
Dmitri Bezinover, Hershey, United States

P-23 Dynamic of Nociceptin Distribution during Liver Transplantation  
Dmitri Bezinover, Hershey, United States

P-24 Early Acute Kidney Injury after Liver Transplantation: Predisposing Factors and Clinical Implications  
Suehana Rahman, London, United Kingdom

P-25 A Crossectional Observational Study of a Series of Living Donor Hepatectomies Assessing the Relationship between Peak Perioperative Serum Lactate Levels with Morbidity and Postoperative Complications  
Raman Raina, New Delhi, India

P-26 A Survey of TEE Usage in Liver Transplantation among US Centers  
Bryan Hill, New York, United States
Scientific Programme

P-27  Single Centre Experience with Intra-operative Continuous Renal Replacement Therapy (CRRT) during Orthotopic Liver Transplantation - Indication Challenge and Outcomes
K.M.E.M Reyntjens, Groningen, Netherlands

P-28  The Effects of Using a Hemoadsobtion Column (CytoSorb®) in Patients with Acute on Chronic Liver Failure. A Pilot Study
Mihai Popescu, Bucharest, Romania

P-29  Recovery Effect of Extracorporeal Membrane Oxygenation (ECMO) on Liver Injury of Donation after Brain-cardiac Death (DBCD)
Li Tong, Guangzhou, China

P-30  Hemodynamic Study of Pulmonary Hypertension in Patients Submitted to Liver Transplantation
Emica Shimozono, Campinas, Brazil

P-31  Effect of IgGM Enriched Immunoglobulin on Hemodynamics in the Perioperative Period
Katharina Willuweit, Essen, Germany

P-32  Intra-aortic Balloon Pump Utilization during Combined Heart-liver Transplantation
Geraldine Diaz, Chicago, United States

P-33  Heparin Dose-response Assessments by Hepcon®HMS Assay in Patients Undergoing Liver Transplantation
Ramona Nicolau, Miami, United States

P-34  Restoration and Maintenance of the Balance between Prohemostatic and Antihemostatic Pathways during Liver Transplantation In Patients with Acute Liver Failure
Anndrei Minou, Minsk, Belarus

Poster Sessions
17:30 - 19:00

Poster Session 1: Basic Sciences

P-35  Prevention of Aged Liver Ischemia Reperfusion Injury by Silencing the Expression of liver TNF-α and Complement 3 Gene in Mice
Dong Chen, Wuhan, China

P-36  Efficient and Safe Delivery of SN38 Prodrugs in Polymeric Nanoparticles to Treat Hepatocellular Carcinoma
Hangxiang Wang, Hangzhou, China

P-37  The Effect of Semimature Dendritic Cell on Transplantation Tolerance of Hepatocytes Differentiated from Mouse Embryonic Stem Cells
Anbin Hu, Guangzhou, China

P-38  Liver Mesenchymal Stem Cells Inhibit T Cell Alloresponses
Timucin Taner, Rochester, United States

P-39  Overexpressing H2AZ Promotes Cancer Cell Proliferation and Inhibits Apoptosis in Intrahepatic Cholangiocarcinoma
Beng Yang, Hangzhou, China
Scientific Programme

P-40 MCM6 Indicates Adverse Tumor Features and Poor Outcomes and Promotes S/G2 Cell Cycle Progression
Zhikun Liu, Hangzhou, China

P-41 Crosstalk between Eag1 and SKP2 is Important for the Regulation of Cell Cycle in Hepatocarcinoma Cells
Hao Chen, Hangzhou, China

P-42 Novel Mouse Models of Liver Disease Induced by Hydrodynamic Tail Vein Injection of Sleeping Beauty System and CRISPR/Cas9 Simultaneously
Chuanhui Peng, Hangzhou, China

P-43 Tumor-specific Delivery of Doxorubicin by Nanoparticles to Treat Hepatocellular Carcinoma
Li Xu, Hangzhou, China

P-44 Improving microRNA Isolation and Quantification for Biomarker Discovery in Liver Transplantation Related Liquids
Henk P. Roest, Rotterdam, Netherlands

P-45 Opposite Roles of mTORC1 and mTORC2 in Liver Ischemia and Reperfusion Injury
Haoming Zhou, Los Angeles, United States

P-46 Toll-like Receptor 4-dependent CCAAT-Enhancer-binding Protein Homologous Protein Activation Induces Hepatocellular Cell Death in Liver Ischemia and Reperfusion Injury
Haoming Zhou, Nanjing, China

P-47 IL-17a Knockout Attenuates Inflammatory Response and Mitochondrial Dysfunction after Hepatic Ischemia-reperfusion Injury
Xin Xiang Yang, Hong Kong, China

P-48 A Proper Dosage of Immunosuppressor Induces a Stable Gut Microbiota after Liver Transplantation
Jinawen Jiang, Hangzhou, China

P-49 The Characterisation of the Autophagy Response during Normothermic Machine Liver Perfusion
Ricky H Bhogal, Birmingham, United Kingdom

P-50 Hyperglycemia Triggered ATF6-CHOP Signaling Worsens Liver Ischemia/Reperfusion Injury by Regulating β-catenin Activity
Jianhua Rao, Nanjing, China

P-51 Identification of IL-28B Genotype Modification in Hepatocytes after Living Donor Liver Transplantation by Laser Capture Microdissection and Pyrosequencing Analysis
King-Wah Chiu, Kaohsiung, Taiwan, Republic of China

P-52 The Transcription Factor Batf and IRF1 Controls IL-10/IL-27 Expression in Dendritic Cells and Transplant Tolerance Induction
Guangxiang Gu, Shanghai, China

P-53 Which Tr1 is Better for Transplant Tolerance Induction: Comparing the Tr1 Generated by IL-27 or TGF-β plus IL-27
Guangxiang Gu, Shanghai, China

P-54 Blocked of Bat3 Expression Promotes Transplant Tolerance by Inducing IL-10 Expression in Dendritic Cells
Guangxiang Gu, Shanghai, China
Scientific Programme

Poster Sessions
17:30 - 19:00

Poster Session 1: Extended Criteria Donor / Disease Transmission

P-55  In-Vitro Parameters Predict in-vivo Blood Flow of a Tissue Engineered Liver Graft in a Pig Model
Dongjin Joo, Rochester, United States

P-56  French Liver Donor Risk Index
Emmanuel Boleslawski, Lille, France

P-57  Long-term Donor and Recipient Outcomes of after Living-donor Liver Transplantation with Anti-HBc Positive Donors with Antiviral Prophylaxis
Vikram Raut, Gurgaon, India

P-58  Metformin Attenuates Liver Ischemia-reperfusion Injury (IRI) by Lower Mitochondrial ROS Production and Reduction of Postischemic Inflammation
Xiang Penghui, Hangzhou, China

P-59  The Impact of Early Allograft Dysfunction on Long-term Patient Morbidity and Mortality Following Liver Transplantation
Geraldine Diaz, Chicago, United States

Poster Session 1: Hepatitis B/C

P-60  Tissue Metabolomic Profile in Occult HBV Infection-related Hepatocellular Carcinoma, Using High-resolution Magic-angle Spinning 1H NMR Spectroscopy
Chao Cen, Hangzhou, China

P-61  The Efficacy of Sofosbuvir Based Therapies (with/without Ribavirin) for Recurrent Hepatitis C (Genotype 1,2,3) in Liver Transplantation Recipient
Tsung-Hui Hu, Kaohsiung, Taiwan, Republic of China

P-62  The Incidence of HBV Infection Declines in Taiwan: From Single Center Database to National Database
Hsieh Chung-Bao, Taipei, Taiwan, Republic of China

P-63  Impact of Hepatitis C Virus (HCV) Antiviral Treatment on the Need for Liver Transplantation (LT)
Marina Berenguer, Valencia, Spain

P-64  Re-evaluating Need for HBIG in Liver Transplant Patients with Detectable HBV Viral Load
Mark Muthiah, Singapore, Singapore

Poster Session 1: Immunosuppression

Poster Sessions
17:30 - 19:00

Poster Area
Scientific Programme

P-65 Preparation and Evaluation of Tacrolimus Encapsulated in Human Serum Albumin for Cardiac Transplantation in Mice
Yaohui Zhang, Hangzhou, China

P-66 Effects of Tacrolimus (FK506) Concentration on CD8+CD28-T Lymphocytes
Jingfeng Liu, Hangzhou, China

P-67 ABO-incompatible Liver Transplantation Using only Rituximab
BORAM Lee, Seongnam, Korea, Republic of

P-68 High Frequency of CD8+ CD28-T-suppressor Cells Maintains Longterm Stable Graft Function after Liver Transplantation
Bingyi Lin, Hangzhou, China

P-69 Individualized Bayesian Approach Dosing of Once-daily Tacrolimus (Advagraf®) in De Novo Liver Transplant Recipients
Gonzalo Rodríguez Laiz, Alicante, Spain

P-70 Comparison of Extended-Release, Once Daily Tacrolimus and Standard Twice Daily Tacrolimus in De Novo Liver Transplant Recipients
Tiong Yeng Lim, London, United Kingdom

P-71 Cyclosporine, an Optional Therapy for Posterior Reversible Encephalopathy Syndrome Related to Tacrolimus
Nerea Hernanz Ruiz, Madrid, Spain

P-72 Can CYP3A5 Genotyping Help in Predicting Therapeutic Tacrolimus Levels and Liver Graft Rejection?
Ankur Shah, Mumbai, India

Poster Sessions
17:30 - 19:00
Poster Area

Poster Session 1: Living Donor

P-73 Influence of Family Relationships on Psychosomatic Characteristics of Donors in Liver Transplantation
Chien-Chih Chen, Kaohsiung, Taiwan, Republic of China

P-74 P4 Stump Approach for Intraoperative Portal Vein Stenting Is Durable and Effective in Pediatric LDLT: An Innovative Technique for a Challenging Problem
Chao-Long Chen, Kaohsiung, Taiwan, Republic of China

P-75 Comparable Short and Long Term Outcomes in Deceased and Living Donor Liver Re-transplantation
Siu Ho Kenneth Chok, HK, Hong Kong

P-76 Risk Factor Analysis of Living Liver Donor Morbidity in a Single Center
Cheng-Maw Ho, Taipei, Taiwan, Republic of China

P-77 Preoperative Liver Biopsy in Living Donor Liver Transplantation: Should Body Mass Index Solely Be a Liver Biopsy Indication?
Birkan Bozkurt, Istanbul, Turkey

P-78 Robotic Living Donor Right Hepatectomy
Gi Hong Choi, Seoul, Korea, Republic of
Scientific Programme

P-79 A Caudate Branch as the Anatomical Landmark for Optimal Bile Duct Division during Donor Hepatectomy: A Prospective Study for its Feasibility
Jae Uk Chong, Seoul, Korea, Republic of

P-80 A Comparative Evaluation of MRI and Liver Biopsy for Liver Fat Estimation in Liver Transplant Donors
Ankush Golhar, New Delhi, India

P-81 Liver Transplantation in Metabolic Disease: A Single Center Experience
Daniela Liccardo, Rome, Italy

P-82 Outcomes and Challenges Faced in Management of Hepatopulmonary Syndrome in Pediatric Liver Transplantation
Neelam Mohan, Gurgaon, India

P-83 Early Regeneration of the Remnant Liver in Donors after Donor Hepatectomy
Nihar Mohapatra, New Delhi, India

P-84 Long-term Outcomes after Living Liver Donation: Analysis of National Data Base
Suk Kyun Hong, Seoul, Korea, Republic of

P-85 Analysis of No-go Cases in Living Donor Liver Transplant due to Potential Donor Problem
Sanghee Song, Seoul, Korea, Republic of

P-86 Perioperative Influence of N-Acetylcysteine on Early Post Transplant Outcome of Recipient In Live Donor Liver Transplantation: A Double Blind Randomized Controlled Trial
Johns Shaji Mathew, Kochi, India

P-87 Lower Limit of the Graft in Adult-to-Adult Living-Donor Liver Transplantation
Nobuhisa Akamatsu, Tokyo, Japan

P-88 Should the A2ALL Definition of Early Allograft Dysfunction (EAD) Replace Dahm Criteria for Small-for-Size Dysfunction (SFSD) as the Outcome Predictor after Adult LDLT?
Sanjay Govil, Chennai, India

P-89 ABO Incompatible Living Donor Liver Transplantation: A Single Center Experience
Gun Hyung Na, Bucheon, Korea, Republic of

Samuele Iesari, Brussels, Belgium

P-91 Venous Outflow Obstruction Following Living Donor Liver Transplantation: Analysis of 1011 Liver Transplant Cases
Sami Akbulut, Malatya, Turkey

P-92 Informed Consent in 1000 Indian Gastrointestinal (GI) Surgical Patients and Living Donor Liver Transplant (LDLT) Recipients, Donors and their Relatives
Samrat Ray, New Delhi, India

P-93 The Impact of Donor Macrovesicular Steatosis in Living Donor Liver Transplantation
MURAT Dayangac, Istanbul, Turkey

P-94 Living Donor Liver Transplantation for Alcoholic Liver Disease
Hillary Braun, San Francisco, United States
Scientific Programme

P-95  Consecutive Cases of Pure Live Donor Right or Extended Right Hepatectomy: Single Surgeon Initial 1-Year Experience
Suk Kyun Hong, Seoul, Korea, Republic of

P-96  The Role of Liver Enzymes During Liver Regeneration in Healthy Liver Donors after Partial Hepatectomy
Ping-Yi Lin, Changhua, Taiwan, Republic of China

P-98  Evaluation of Morphological and Microbiological Characteristics of Gall Bladder in Living Liver Donors: A Prospective Descriptive Study
Sami Akbulut, Malatya, Turkey

P-99  Beyond Right versus Left: Living Liver Donor Outcomes Vary by Gender and Remnant Volume
Viola Huang, Kaohsiung, Taiwan, Republic of China

P-100 Clinical Study on Standard of Hepatic Vein Reconstruction in Adult Right Lobe Living Donor Liver Transplantation
Xiaofeng Xu, Hangzhou, China

Poster Sessions
17:30 - 19:00
Poster Area

Poster Session 1: Malignancies

P-101  Safety and Validity Evaluation for Nature Killer Cell Therapy for Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation
Guo-Ying Wang, Guangzhou, China

P-102  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Liver Transplantation for Hepatocellular Carcinoma. A European Multicentric Study
Fabio Melandro, Rome, Italy

P-103  Prognostic Effect of TACE-induced Complete Pathologic Response in Patients Undergone Liver Resection and Transplantation for Hepatocellular Carcinoma
Woo-Hyoung Kang, Seoul, Korea, Republic of

P-104  Pilot Feasibility Study Demonstrating Improved Survival Outcomes with Liver Transplantation for Advanced Intrahepatic Cholangiocarcinoma Treated with Neoadjuvant Chemotherapy
Keri E. Lunsford, Houston, United States

P-105  Prognostic Value of Plasma Cell-free DNA Methylation Markers in Hepatocellular Carcinoma Following Liver Transplantation
Xiao-Xiao Lu, Hangzhou, China

P-106  Microwave Ablation and Salvage Transplantation for Patients with Hepatocellular Carcinoma
Alessandra Bertacco, New Haven, United States

P-107  Prognostic Model for the Managing of Patients Affected by Hepatocellular Carcinoma and Suitable for Both Liver Resection and Liver Transplantation
Stefano Di Sandro, Milan, Italy

P-108  Potassium Channel KCa3.1 Promotes Cell Cycle Progression by Targeting SKP2 and Invasiveness through EMT Pathway in Hepatocellular carcinoma
Penghong Song, Hangzhou, China
Scientific Programme

P-109  KCa3.1 as an Effective Target for Inhibition of Growth and Progression of Intrahepatic Cholangiocarcinoma
Yehui Du, Hangzhou, China

P-110  Living Donor Liver Transplantation after Successful Downstaging Using Targeted Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
Prashant Bhangui, Medanta, India

P-111  Diagnostic Predictability of Blood Tumor Markers for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Undergoing Liver Transplantation
Yo-Han Park, Busan, Korea, Republic of

P-112  Clinical Value of Liquid Biopsy Techniques in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation
Shaojun Shi, Shanghai, China

P-113  Aberrant Promoter Methylation of ACTL6B Demonstrates Diagnostic and Prognostic Value for Hepatocellular Carcinoma
Xiao-Xiao Lu, Hangzhou, China

P-114  Treatment of Hepatocellular Carcinoma in Children - Analysis of Criteria for Transplantation - 26 Years of Experience in Single Center
Dorota Broniszczak-Czyszek, Warsaw, Poland

P-115  The Prognostic Value of Gd-EOB-DTPA Enhanced MRI in Prediction of Patients´ Outcome Following Liver Transplantation for HCC
Woo Kyoung Jeong, Seoul, Korea, Republic of

P-116  Mybbp1a Regulates Activity of AKT Signal Pathway by Inhibiting IGFBP5 Secretion in Hepatocellular Carcinoma
Xiaoyu Weng, Hangzhou, China

Poster Sessions
17:30 - 19:00

Poster Session 1: Outcomes

P-117  36 Hours of Ex-vivo Warm Cellular Perfusion of Swine Liver Using the Organ Care System (OCS™) Liver With Excellent Functional, Metabolic and Histological Outcomes
Joseph Magliocca, Atlanta, United States

P-118  TFCP2 Genetic Polymorphism is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma
Feng Gao, Hangzhou, China

P-119  Risk Stratification of de novo Non-melanoma Skin Cancer Following Liver Transplantation: Analysis of the UNOS Database
Tomohiro Tanaka, Iowa City, United States

P-120  The Use of Deep Neural Networks to Predict Post-liver Transplant Mortality
Christopher Wray, Los Angeles, United States

P-121  A Comprehensive Performance Index to Evaluate Liver Transplant Programs
John Renz, Chicago, United States
<table>
<thead>
<tr>
<th>P-122</th>
<th>Use Of Donors after Cardiac Death (DCD) Maastricht Type II in Recipients Older than 60 Years and Older than 65</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maria García-Conde, Madrid, Spain</td>
</tr>
<tr>
<td>P-124</td>
<td>Significance of Lactate Production during Liver Transplantation: Look at the Gut Rather than the Liver</td>
</tr>
<tr>
<td></td>
<td>François Faitot, Strasbourg, France</td>
</tr>
<tr>
<td>P-125</td>
<td>Early Improvement in Insulin Requirements after Liver Transplantation in Patients with Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td></td>
<td>Mauro Enrique Tun-Abraham, London, Canada</td>
</tr>
<tr>
<td>P-126</td>
<td>Expression of Galectin-9 in Recipient Liver is Related to Liver Allograft Rejection after Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Yifan Peng, Hangzhou, China</td>
</tr>
<tr>
<td>P-127</td>
<td>Equivalent Renal Allograft Survival Following Simultaneous Liver Kidney Transplantation Compared to Matched Kidney Transplant Alone Recipients: A Match Cohort Analysis</td>
</tr>
<tr>
<td></td>
<td>Keri E. Lunsford, Houston, United States</td>
</tr>
<tr>
<td>P-128</td>
<td>Association between Donor TLR-4 rs 913930 Polymorphism and Post Liver Transplant Complications in Belarus</td>
</tr>
<tr>
<td></td>
<td>Denis Efimov, Minsk, Belarus</td>
</tr>
<tr>
<td>P-129</td>
<td>Early Acute Cellular Rejection (eACR) as a Marker of Immunologic Competency Following Liver Transplantation (LT)</td>
</tr>
<tr>
<td></td>
<td>Varvara Kirchner, Minneapolis, United States</td>
</tr>
<tr>
<td>P-130</td>
<td>Donor Mannose-binding Lectin (MBL) Gene Polymorphisms Increase the Risk of Bacterial Infections and Bacterial Infection-related Mortality after Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Julissa Lombardo, Barcelona, Spain</td>
</tr>
<tr>
<td>P-131</td>
<td>Endothelial Function as a Predictor of Cirrhosis Decompensation and Cirrhosis-related Cardiomyopathy: A Single-center Prospective Study of 115 Patients</td>
</tr>
<tr>
<td></td>
<td>Kymberly Watt, Rochester, United States</td>
</tr>
<tr>
<td>P-132</td>
<td>Usefulness of Bundled Strategies against Infection after Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Toshimi Kaido, Kyoto, Japan</td>
</tr>
<tr>
<td>P-133</td>
<td>Utilization of Technical Variant Allografts for Adult and Pediatric Liver Transplantation: A 10-year Experience</td>
</tr>
<tr>
<td></td>
<td>Christopher Ibarra, New Haven, United States</td>
</tr>
<tr>
<td>P-134</td>
<td>Experience of Split Liver Transplantation in a High-volume Living-donor Liver Transplantation Center in Korea</td>
</tr>
<tr>
<td></td>
<td>Eun-Kyung Jwa, Seoul, Korea, Republic of</td>
</tr>
<tr>
<td>P-135</td>
<td>Urinary MicroARNs Potential Biomarkers to Improve the Prediction of Kidney Function Recovery in Cirrhotic Patients Undergoing Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Clement Lejealle, Clichy, France</td>
</tr>
<tr>
<td>P-136</td>
<td>Technical Refinement to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation: New Simplified One-orifice Venoplasty</td>
</tr>
<tr>
<td></td>
<td>Dong Lak Choi, Daegu, Korea, Republic of</td>
</tr>
<tr>
<td>P-137</td>
<td>Six Minute Walk Distance Improves after Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Mohanad T Al-Qaisi, Phoenix, United States</td>
</tr>
</tbody>
</table>
Scientific Programme

P-138 How to Treat Antibody-mediated Rejection after Liver Transplantation
Katharina Stauffer, Vienna, Austria

P-139 Short-term Outcome after First Liver Transplantation in Adults in Korea: Risk Factors of In-hospital Mortality
Eunmi Gil, Seoul, Korea, Republic of

P-140 Management of Coronary Artery Disease in Prospective Living Donor Liver Transplant Recipients - Experience of 861 Cases
Sanjeev Rohatgi, Gurgaon, India

P-141 Impact of Post-reperfusion Hyperglycemia on Transient Post-transplantation Hyperglycemia and Post-transplantation Diabetes mellitus after Liver Transplantation
Roberta Angelico, Rome, Italy

P-142 Fast-track Liver Transplantation Can Be the Standard of Care: Our Initial Results
Gonzalo Rodríguez Laiz, Alicante, Spain

P-143 The Impact of Pre-Existing Diabetes Mellitus on Liver Transplant Candidates with Hepatocellular Carcinoma: An Intention-to-Treat Analysis of the US National Database
Zhiwei Li, Hangzhou, China

P-144 CMV Reactivation Increases Cardiovascular Disease in Liver Transplantation (LT)
Victoria Aguilera, Valencia, Spain

P-145 Post-operative Thrombocytopenia is an Indicator of Adverse Outcomes after Liver Transplantation
Alexa Strachan, London, United Kingdom

P-146 Outcomes of Living Donor Liver Transplantation for Acute on Chronic Liver Failure Based on EASL-CLIF Diagnostic Criteria
Abu Bakar Hafeez Bhatti, Islamabad, Pakistan

P-147 Expanded Criteria for HCC In Liver Transplantation
Mehmet Haberal, Ankara, Turkey

P-148 Liver Transplantation for Babies Weighing Less Than 10 kg
Mehmet Haberal, Ankara, Turkey

P-149 Comparison between Cadaveric Whole Liver Graft and Live Donor Partial Liver Graft Transplantation in High Risk Patients with MELD Score More than 40
Chul Soo Ahn, Seoul, Korea, Republic of

P-150 A Multicenter, Randomized, Placebo-controlled Trial of Extract of Japanese Herbal Medicine Daikenchuto to Prevent Bowel Dysfunction after Adult Liver Transplantation (DKB 14 Study)
Takamasa Mizota, Tokyo, Japan

P-151 Racial and Ethnic Disparities in Access to Liver Transplantation for Patients with End Stage Liver Disease: Pre-share 35 vs. Post-share 35
Yefei Zhang, Houston, United States

P-152 Overexpression of CLIC1 Positively Correlates with Recurrence of Hepatocellular Carcinoma
Xuyong Wei, Hangzhou, China

P-153 Liver TNF-α Expression Predicts Acute Allograft Rejection and Graft Survival
Mehmet Haberal, Ankara, Turkey
Scientific Programme

Poster Sessions
17:30 - 19:00

Poster Session 1: Patient Selection / Organ Allocation / Organ Recovery

P-154 Regulatory B Cell Proportions Predict Occurrence of Graft versus Host Disease and Acute Allograft Rejection in Liver Transplantation
Haoming Zhou, Nanjing, China

P-155 The Use of a Hemoglobin-based Oxygen Carrier in a Human Liver Model of Normothermic Machine Perfusion
Richard Wallace Laing, Birmingham, United Kingdom

P-156 Preoperative Tumor Markers of Hepatocellular Carcinoma for Use as Selection Criteria in Living Donor Liver Transplantation
Seok-Hwan Kim, Seoul, Korea, Republic of

P-157 Impact of Preservation Solution On Early Allograft Dysfunction (EAD) and Graft Survival after Liver Transplantation (LT) Using Expanded-criteria-Donors (ECD)
Vincent Karam, Villejuif, France

P-159 Cardiopulmonary Exercise Performance and Nutritional Status Is Significantly Associated with Severity of Liver Disease in Transplant Assessment Patients
Luke Walls, Edinburgh, United Kingdom

P-160 Predictors of Dropout from the Liver Transplant Waitlist for Hepatocellular Carcinoma in Long Wait Time Regions: Identifying a Group with a Low Risk of Dropout
Neil Mehta, San Francisco, United States

P-161 Trends in Liver Transplant Donor Offers over Time: An Australian Experience
Ken Liu, Sydney, Australia

P-162 Phosphatidylethanol Holds Promise as a Sensitive and Specific Biomarker for Monitoring Sobriety of Liver Transplant Candidates
Alexander Bernsmeier, Kiel, Germany

P-163 Split Liver Transplantation Is an Effective Option in LDLT Predominant Centres with Limited Availability of Deceased Donor Grafts
Ramkiran Cherukuru, Chennai, India

P-164 Perfusate Secretome Analysis of Discarded Human Donor Livers Undergoing Normothermic Machine Perfusion
Richard Wallace Laing, Birmingham, United Kingdom

Poster Sessions
17:30 - 19:00

Poster Session 1: Pediatrics

P-166 Domino Liver Transplantation from a Child with Propionic Acidemia to a Child with Idiopathic Fulminant Hepatic Failure
Marina Moguilievitch, Bronx, United States

P-167 Successful Living Donor Liver Transplantation for a Korean Infant with Oxysterol 7α-hydroxylase Deficiency
Kyung Mo Kim, Seoul, Korea, Republic of
Scientific Programme

P-168  Surgical Outcome of Pediatric Liver Transplantation: Single Center Experience
Hakan Sozen, Ankara, Turkey

Poster Sessions
17:30 - 19:00
Poster Area

Poster Session 1: Radiology / Interventional Radiology

P-169  Endovascular Approach to Giant Splenic Artery Aneurysm after Liver Transplantation
Sami Akbulut, Malatya, Turkey

P-170  Functional Ultrasound Imaging as an Innovative Tool to Assess Hepatic Microcirculation Performances during and after Liver Transplantation Procedures
Giacomo Concone, Milan, Italy

P-171  MR Cholangiography in Potential Liver Donors: Quantitative and Qualitative Improvement with Administration of Oral Effervescent Agent
Heon-Ju Kwon, Seoul, Korea, Republic of

Poster Sessions
17:30 - 19:00
Poster Area

Poster Session 1: Recurrent Disease / Pathology

P-172  Risk of Alcohol Relapse and Outcome after Living-donor Liver Transplantation for Patients with Alcoholic Cirrhosis
Toshimi Kaido, Kyoto, Japan

P-173  Protein Induced by Vitamin K Antagonist-II (PIVKA-II) as a Predictor of Recurrence of Hepatocellular Carcinoma after Liver Transplantation
Laura Núñez-Gómez, Madrid, Spain

P-174  HCC Recurrence after Liver Transplantation: Risk Factors, Characteristics and Outcome
Faouzi Saliba, Villejuif, France

P-175  Hepatic Encephalopathy in a Liver Transplant Recipient with Normal Graft Function
Laura Núñez-Gómez, Madrid, Spain

Poster Sessions
17:30 - 19:00
Poster Area

Poster Session 1: Surgical Techniques / Complications

P-176  The Effects of Sirolimus on Weight Gain Following Liver Transplant: Limiting a Significant Comorbidity
Greg J McKenna, Dallas, United States

P-177  Robotic Pure MIS Right Hepatectomy for Living Donor of Liver
Yao-Ming Wu, Taipei, Taiwan, Republic of China
P-178 Lessons from Complications of Initial Series of Pure Laparoscopic Living Donor Hepatectomy Performed by an Experienced Surgeon in Open Surgery
Kwang-Woong Lee, Seoul, Korea, Republic of

P-179 Portal Decompression with Passive Mesenterico-saphenous Shunt: An Efficient Alternative to Temporary Portacaval Anastomosis
Francois Faitot, Strasbourg, France

P-180 Microsurgical Hepatic Artery Reconstruction in Pediatric Liver Transplantation: Analysis of the First 115 Consecutive Cases by a Single Surgeon
Mingxuan Feng, Shanghai, China

P-181 Auxiliary Partial Orthotopic Liver Transplantation: A Single Center Experience
Wei Qu, Beijing, China

P-183 Failure to Rescue in Living Donor Liver Transplantation: A Single Center Experience
Abu Bakar Hafeez Bhatti, Islamabad, Pakistan

P-184 Results of Biliary Reconstruction with PTFE Graft in Liver Transplantation
Mehmet Haberal, Ankara, Turkey

P-185 Long Term Result of Stent Insertion in Patients with Early and Late Hepatic Venous Outflow Obstruction after LDLT
Kyeong Sik Kim, Seoul, Korea, Republic of

P-186 Risk Factors for Biliary Complications after Orthotopic Liver Transplantation: A Single-center Cohort of 500 Transplants
Amaury Castro Silva Filho, Fortaleza, Brazil

P-187 Incisional Hernia in Adult Liver Transplant Recipients
JI SOO Lee, Seoul, Korea, Republic of

P-188 The Start Times of Liver Transplantation and Postoperative Complications
Zhong Haigang, Hangzhou, China

P-189 Morbidity after Living Donation: Incisional Hernias in Living Liver Donors
Hillary Braun, San Francisco, United States

P-190 Hepatic Artery Occlusion in Liver Transplantation – What Counts More: Type of Reconstruction or Severity of Recipient Disease?
Christian Eugen Oberkofler, Zürich, Switzerland

P-191 Impact of Early Allograft Dysfunction on Graft and Patient Outcomes after Liver Transplantation: A Meta-analysis
Zhiyong Guo, Guangzhou, China

P-192 Impact of Pre Transplant Transarterial Chemoembolization on Hepatic Arterial Blood Flow and Outcomes in Liver Transplantation
Siddharth Jain, Delhi, India

P-193 Piggy Back Anastomosis on the Right Hepatic Vein (PB-RHV) Facilitates Orthotopic Implantation of Small-sized Grafts
Olivier Soubrane, Clichy, France

P-194 A Step-up Approach for Complex Graft Biliary Anatomy Using Microsurgical Biliary Reconstruction in Living Donor Liver Transplantation
Deniz Balci, Ankara, Turkey
<table>
<thead>
<tr>
<th>P-195</th>
<th>Analysis of the Early Postoperative Course after DCD Liver Transplantation Using the Novel Comprehensive Complication Index</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Marit Kalisvaart, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>P-196</td>
<td>Ex-situ Arterial Reconstruction during Normothermic Perfusion of the Liver - Taking Surgical Technique to the Next Level</td>
</tr>
<tr>
<td></td>
<td>David Nasralla, Oxford, United Kingdom</td>
</tr>
<tr>
<td>P-197</td>
<td>Scoring System for Predicting Persistent Ascites after Living Donor Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Yi-Ju Wu, Kaohsiung, Taiwan, Republic of China</td>
</tr>
<tr>
<td>P-198</td>
<td>What Happened in 133 Consecutive Hepatic Artery Reconstruction in Liver Transplantation in One Year?</td>
</tr>
<tr>
<td></td>
<td>Tsan-Shiun Lin, Kaohsiung, Taiwan, Republic of China</td>
</tr>
<tr>
<td>P-199</td>
<td>Portal Vein Stenting is a Significant Risk Factor for Biliary Stricture in Adult Living Donor Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Min-Ho Shin, Gwangju, Korea, Republic of China</td>
</tr>
<tr>
<td>P-200</td>
<td>Diffuse Intrahepatic Biliary Stricture is Associated with Inferior Survival in ABO-incompatible Liver Transplantation: A Single-center Experience</td>
</tr>
<tr>
<td></td>
<td>Wei Zhang, Hangzhou, China</td>
</tr>
<tr>
<td>P-201</td>
<td>Comparing Renal Function after Liver Transplantation: Modified Piggyback versus Conventional Techniques without Venovenous Bypass</td>
</tr>
<tr>
<td></td>
<td>Deok Gie Kim, Seoul, Korea, Republic of China</td>
</tr>
<tr>
<td>P-202</td>
<td>Pre-operative Platelet and Portal Venous Velocity were Affected Short-term Liver Volumetric Recovery in Right Lobe Living Donor Hepatectomy</td>
</tr>
<tr>
<td></td>
<td>Kaman Kuok, Changhua, Taiwan, Republic of China</td>
</tr>
<tr>
<td>P-203</td>
<td>Effective Thrombolytic Therapy of Hepatic Artery Thrombosis after Liver Transplantation a Single Center Experience</td>
</tr>
<tr>
<td></td>
<td>Maogen Chen, Guangzhou, China</td>
</tr>
<tr>
<td>P-204</td>
<td>Surgical Strategies for Dual Portal Venous Branches in Living Donor Liver Transplantation Using Right Lobe Graft</td>
</tr>
<tr>
<td></td>
<td>Kwangho Yang, Yangsan, Korea, Republic of</td>
</tr>
<tr>
<td>P-205</td>
<td>Systematic Review and Meta-analysis of Aortohepatic Conduits in Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Tim Reese, Zürich, Switzerland</td>
</tr>
</tbody>
</table>
Thursday, 25 May 2017

Vanguard Sessions
06:30 - 08:00
Panorama Hall

Vanguard Grand Round Case Presentations

Chairs:
Gonzalo Sapisochin, Toronto, Canada
Adrienne Carr, Halifax, Canada

Case 1: Multifocal liver lesions in Abernathy malformation: the role for liver transplantation
Hermien Hartog, Rotterdam, Netherlands
Matej Kocik, Prague, Czech Republic
06:30

Case 2: Elderly, anti-HBcore+, anti-HCV+ graft: can we use it?
Alberto Zanetto, Padova, Italy
Marina Berenguer, Valencia, Spain
07:00

Case 3: What happens when we run out of options for vascular access in re-transplantation?
Andrew Bailey, London, United Kingdom
Yoogoo Kang, Philadelphia, United States
07:30

Others
07:30 - 09:30
North Hall

TEE Workshop

Chairs:
Jeron Zerillo, New York, United States
Dmitri Bezinover, Hershey, United States

Transesophageal echocardiography (TEE)
Sang Kim, New York, United States
Cindy Wang, New York, United States
07:30

Plenary Abstract Session
08:00 - 09:30
Congress Hall

Plenary Abstract Session 1

Chairs:
Patrizia Burra, Padova, Italy
Jiří Froněk, Prague, Czech Republic

O-1 Results of the Initial Phase of the Portable Organ Care System (OCS™) Liver PROTECT Pivotal Trial
James Markmann, Boston, United States
08:00
Scientific Programme

O-2 The Final Histological Necrosis of the Target Hepatocellular Carcinoma as a Predictor of Tumour Recurrence after Liver Transplantation
Tommaso Maria Manzia, Rome, Italy

O-3 Conversion to Everolimus (EVL) after Liver Transplantation (LT) in the Real Life: Data from the Everoliver Multicenter Observational Registry
Faouzi Saliba, Villejuif, France

O-4 Long-term Outcomes of Allograft Fibrosis after Paediatric Liver Transplantation
Jeremy Rajanayagam, Melbourne, Australia

O-5 Comparison of PTFE Grafts with Autologous Veins for Venous Outflow Reconstruction in Right Lobe Living Donor Liver Transplant
Gaurav Sood, Delhi, India

O-6 Epigenetic Modifications as Key Regulator of Molecular Pathways Associated with Ischemia Reperfusion Injury after Liver Transplantation
Debalina Bagchi, Charlottesville, United States

O-7 Preliminary Results of the UK ‘REVIVE’ Trial for Normothermic Oxygenated Perfusion of Deceased Donor Livers Using the Portable Organ Care System (OCS™) Liver
Dhakshinamoorthy Vijayanand, Leeds, United Kingdom

Rising Star Symposium
09:30 - 11:30
Congress Hall

Rising Star Symposium

Chairs:
Michael R. Charlton, Chicago, United States
Jan Lerut, Bruxelles, Belgium

O-8 Human Hepatocytes Co-encapsulated with Mesenchymal Stromal Cells in Alginate Microbeads for the Treatment of Acute Liver Failure in Children
Valeria Iansante, London, United Kingdom
Anil Dhawan, London, United Kingdom

O-9 Outcomes from a Multinational Randomised Controlled Trial Comparing Normothermic Machine Perfusion with Static Cold Storage in Human Liver Transplantation
David Nasralla, Oxford, United Kingdom
Peter Friend, Oxford, United Kingdom

O-10 Bile Duct Strictures after Liver Transplantation are Associated with a Donor Glypican-6 Polymorphism Linked to the Biliary Stem Cell Niche
Jasmijn Selten, Rotterdam, Netherlands
Luc van der Laan, Rotterdam, Netherlands

O-11 Analysis of Caudate Lobe Biliary Anatomy and its Implication in Living Donor Liver Transplantation
Kausar Makki, Noida, India
Vivek Vij, Noida, India
Scientific Programme

O-12 Diagnostic Utility of Simple Non-invasive Fibrosis Scores in Post-liver Transplant Patients with Non-alcoholic Fatty Liver Disease (NAFLD)  
Zita Galvin, Toronto, Canada  
10:50

O-13 The Feasibility of Medial Segment Graft for Liver Transplantation Materialized by Three-dimensional Printing  
Yi-Ting Yeh, Taipei, Taiwan, Republic of China  
Cheng-Yen Chen, Taipei, Taiwan, Republic of China  
11:10

Others  
11:30 - 11:45  
Congress Hall

In memory of Thomas Earl Starzl

In memory of Thomas Earl Starzl  
John Fung, Chicago, United States  
11:30

Posters Sessions  
11:30 - 12:00  
Poster Area

Surgical Video Presentations Session 1

eP-2 Total Laparoscopic Donor Right Hepatectomy for Modified Extended Right Graft  
JAI YOUNG Cho, Seongnam, Korea, Republic of  

Poster Sessions  
11:30 - 12:00  
Poster Area

Poster Session 2: Acute Liver Failure

P-206 Liver Transplantation for Acute Liver Failure (ALF)  
Rasim Farajov, Izmir, Turkey  

P-207 Niacin-associated Acute Hepatotoxicity Leading to Emergency Liver Transplantation  
Silvia Schaffellner, Graz, Austria  

P-208 Living Donor Liver Transplantation for Mushroom Intoxication Caused Acute Liver Failure  
Abuzer Dirican, MALATYA, Turkey  

P-209 Aflatoxicosis Induced Acute Liver Failure: A Case of a Tropical Liver Disease Presenting in an European Country  
Amedeo Carraro, Verona, Italy

Poster Sessions  
11:30 - 12:00  
Poster Area

Poster Session 2: Anesthesia / Critical Care Medicine

Page 19 / 74
Scientific Programme

P-210  Incidence and Predictive Factors of Postreperfusion Syndrome in a Multicenter Liver Transplant Study
Antoni Sabaté, Barcelona, Spain

P-211  Belmont-associated Hypotension
Nicolette Schlichting, New York, United States

P-212  Detection of Viral Infection in Transplanted Patients Using Support Vector Machines Classification
Anli Yang, Guangzhou, China

P-213  Computer-assisted Diagnosis of Candidiasis in Transplanted Patients Using Support Vector Machine Classification
Anli Yang, Guangzhou, China

P-214  MELD (i), MELD-Na, New (UNOS) MELD, MELD-XI Score as a Predictor of Survival after Liver Transplantation
Gebhard Wagener, New York, United States

P-215  The Potential Benefits of a Hemoadsorption Column in a Patient with Severe Inflammatory Syndrome due to Graft Dysfunction and Massive Transfusion after Liver Transplantation
Mihai Popescu, Bucharest, Romania

P-216  Effect of Extracorporeal Membrane Oxygenation (ECMO) with Occlusion Balloon Catheter on Liver Grafts in the Donation after Brain Death Followed by Cardiac Death (DBCD)
Chang Jie Cai, Guangzhou, China

P-217  Pilot Study of Abdominal Wall Blocks for Following Living-Liver Donation
Laurence Torscher, Rochester, United States

P-218  Utility of Surgical Apgar Score in Orthotopic Liver Transplantation
Jun Li, Chengdu, China

P-219  Transfusion Requirements and Outcomes in Adult Liver Transplantations Since the Introduction of Fibrinogen Concentrate in Singapore: A Single-centre Experience
Yi Wei Tan, Singapore, Singapore

P-220  Role of High Preoperative Bilirubin Values in Protection against Ischemia Reperfusion Injury Following Live Donor Liver Transplantation
Nitin Shanker, New Delhi, India

P-221  Minimizing Blood Loss and Transfusion Requirement in Patients Undergoing Liver Transplantation: Role of Prothrombin Complex Concentrate
Piyush Srivastava, Noida, India

P-222  Hepatitis E Associated Fulminant Hepatic Failure in Pregnancy: Feasibility of LDLT
Sonali Saraf, Thane, India

P-223  Effect of Intraoperative Hypothermia on Patient Outcome in Living Donor Liver Transplant
Vijay Vohra, Gurgaon, India

P-224  Transfusion Prediction Model in Orthotopic Liver Transplantation Based on Thromboelastometry: Prospective Validation Study
Annabel Blasi, Barcelona, Spain

P-225  High Risk Factors of Blood Infection in Chinese Citizen Voluntary Donors: A Single-centre Retrospective Study
Z.X Tang, Guangzhou, China
Scientific Programme

P-226 Impact of the Use of Cell Salvage on Transfusion Requirements in Liver Transplant
Lakshmi Kumar, Kochi, India

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 2: Basic Sciences

P-228 Loss of Bat3 Could Promote Transplant Tolerance by Regulating CD4+ T Cells Function
Guangxiang Gu, Shanghai, China

P-229 Differential Expression of Long Noncoding RNAs during Cardiac Rejection
Guangxiang Guguangxiang, Shanghai, China

P-230 Impact of SS18L1 Polymorphism in Predicting Prognosis of Hepatocellular Carcinoma
Min-Su Park, Seoul, Korea, Republic of

P-231 Are Involved Mitochondrial GSK3beta and VDAC in the Protection of Liver Graft in Rat Liver Orthotopic Liver Transplantation?
Arnau Panisello-Rosello, Barcelona, Spain

P-232 Neu5GCKO Reduces Erythrocyte Sequestration, Modulates Platelet Activation, and Augments Synthetic Function in an Ex Vivo Pig-to-Human Xenoperfusion Model
Arielle Cimeno, Baltimore, United States

P-233 Long noncoding RNA CASC15 is Upregulated in Hepatocellular carcinoma and Promotes the Development of Tumor
Tianyu He, Hangzhou, China

P-234 Pseudogene PDIA3P1 Enhances Proliferation, Migration and Invasion in Hepatocellular Carcinoma
Yang Kong, Hangzhou, China

P-235 IGL-1 Solution Enhances Fatty Liver Graft Preservation against Cold Ischemia Injury when Compared with HTK Solution: Some Answers to Preservation Mechanisms
Alexandre Lopez, Paris, France

P-236 The Long Non-coding RNA-CASC15 Promotes the Development of Intrahepatic Cholangiocarcinoma
Yuan Zhang, Hangzhou, China

P-237 Omics and Translational Approaches for Appropriate Biomarker Discovery in Liver Transplantation
Toshiaki Nakano, Kaohsiung, Taiwan, Republic of China

P-238 PPAR-γ Agonist Attenuates Hepatic Ischemia-reperfusion Injury in a Mouse Model by Regulating Kupffer Cell Polarization
Ivan Linares, Toronto, Canada

P-239 Experimental Study of Hepatocyte Proliferation Regulated by miR26a
Jian Zhou, Guangzhou, China

P-240 Effect of PNPLA3 I148M Polymorphism on Histologically Proven NAFLD in Liver Transplant Recipients
Hyeyoung Kim, Seoul, Korea, Republic of
Scientific Programme

P-241 Surgical Techniques of Allogeneic Liver Transplantation in Nonhuman Primate Models
Hyeyoung Kim, Seoul, Korea, Republic of

P-242 Genes Associated with Prognosis of Hepatocellular Carcinoma: Validation of Microarray Results Using Quantitative Real Time RT-PCR
Koo Jeong Kang, Daegu, Korea, Republic of

P-243 Dual Roles of Calreticulin in Liver Fibrosis
Kuang-Tzu Huang, Kaohsiung, Taiwan, Republic of China

P-244 The Epigenetic and Autophagic Regulation in FVII-induced Epithelial to Mesenchymal Transition by miR-135a in Hepatocellular Carcinoma
Kuang-Den Chen, Kaohsiung, Taiwan, Republic of China

P-245 AR-42 Induces Apoptosis and Cell Cycle Arrest in Pancreatic Cancer
Yingcai Yan, Hangzhou, China

P-246 Prenylcysteine Oxidase 1 Suppresses Tumor Growth and Correlates with Clinical Prognosis of Hepatocellular Carcinoma
Jianguo Wang, Hangzhou, China

Poster Sessions
11:30 - 12:00

Poster Session 2: Extended Criteria Donor / Disease Transmission

P-247 Impact of Donor Pre-procurement Cardiac Arrest on Clinical Outcomes In Liver Transplantation
Burcin Ekser, Indianapolis, United States

P-248 Application of ICG Detection in Evaluating Early Prognosis in Patients with Fatty Liver Disease after Liver Transplantation
Xiaofeng Zhu, Guangzhou, China

P-249 Pre-emptive Therapy versus Prophylactic Therapy for Cytomegalovirus Infection in Liver Transplant Recipients: A Randomized Clinical Trial of Safety and Efficacy
Niteen Kumar, Delhi, India

P-250 How a New Liver Center Extends the Limits of Liver Transplantation
Francisco Juan Mattera, Florencio Varela, Argentina

P-251 Liver Transplantation beyond MELD 40: Results at a High Volume Center in the United States
Joseph Scalea, Baltimore, United States

Poster Sessions
11:30 - 12:00

Poster Session 2: Immunosuppression

P-257 Identification of a Stable Gene Signature of Transplant Tolerance to Liver Allograft by Meta-analysis
Guangxiang Gu, Shanghai, China
Scientific Programme

P-258  Rituximab Desensitization for Liver Transplantation with Preformed Donor Specific Antibodies
Yasuhiro Ogura, Nagoya, Japan

P-259  ABO Incompatible Liver Transplantation using Plasma Exchange and Anti-CD20 Monoclonal Antibody
Yang-Seok Koh, Jeonnam, Korea, Republic of

P-260  The Experience of mTOR Inhibitors Combined with Tacrolimus in Living Donor Liver Transplantation
Wei Feng Li, Kaohsiung, Taiwan, Republic of China

P-261  Effects of Conversion from Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplantation Recipients
LUNG-CHIH Li, Kaohsiung, Taiwan, Republic of China

P-262  Safety of Everolimus in Living Donor Liver Transplantation Recipients with Severe Renal Dysfunction with Low Estimated Glomerular Filtration Rate: Can Everolimus Help in Renal Recovery?
Ashok Thorat, Taichung, Taiwan, Republic of China

P-263  Is Once-daily Extended-release Tacrolimus Better than Twice-daily Standard-release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials
Guangxiang Gu, Shanghai, China

P-264  Risk Factors for the Adverse Events after Conversion from Twice-daily to Once-daily Tacrolimus in Stable Liver Transplantation Patients
Suk-Won Suh, Seoul, Korea, Republic of

P-265  Tacrolimus Dose Requirement for Indian Liver Transplant Recipients is Less than their Western Counterparts and Varies with CYP3A5 Genotype
Sushil Dubey, Mumbai, India

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 2: Living donor

P-267  Transarterial Chemoembolization with Drug-eluting Beads for Living Donor Liver Transplantation
Marirose Lazo, Kaohsiung, Taiwan, Republic of China

P-268  The Outcome of Living Donor Liver Transplantation Using Treated Fatty Liver Grafts
Yuki Fujii, Sapporo, Japan

P-269  Subjective Experiences and Outcomes of Donors of Adult Living Donor Liver Transplants (LDLT)
Jia Hao Law, Singapore, Singapore

P-270  Clinical Experience and Feasibility of Totally Laparoscopic Living Donor Right Hepatectomy
Heon Tak Ha, Daegu, Korea, Republic of

P-271  Is Left Donor Hepatectomy Safer than Right Donor Hepatectomy: Experience from a High Volume Living Donor Liver Transplant Program
Sanjay Kumar Yadav, Gurgaon, India
The 2017 Joint International Congress of ILTS, ELITA & LICAGE  
May 24 - 27, 2017,  
Prague, Czech Republic

Scientific Programme

P-272  Initial Experience in Live Liver Donors with the Sickle Cell Trait  
Mark Sturdevant, Riyadh, Saudi Arabia

P-273  Total Laparoscopic Donor Right Hepatectomy in a Large Single-center for Laparoscopic Hepatectomy  
YoungRok Choi, Sungnam-Si, Korea, Republic of

P-274  Case Report: First Dual Graft Liver Transplantation in Egypt  
Amr Abdelaal, Cairo, Egypt

P-275  Role of Stent-less Biliary Anastomosis in Ending the Achilles Heel of LDLT  
Hatem Sayed, Cairo, Egypt

P-276  Recovery from Hypophosphatemia as a Predictor of Post-operative Morbidity in Live Donor Hepatectomyt  
Oscar Serrano, Minneapolis, United States

P-278  Transarterial Embolization of Intrahepatic AP Shunt in Living Donor Liver Transplant  
Yu Fan Cheng, Kaohsiung, Taiwan, Republic of China

P-279  Donor Safety and Recipient Liver Function Following Right-lobe Liver Transplantation from Living Donors with Gilbert Syndrome  
Tae-Yong Ha, Seoul, Korea, Republic of

P-280  Biliary Complications in Live Donors Following Donor Hepatectomy  
Dinesh Balakrishnan, Kochi, India

P-281  Demographic Data of 3903 Live Liver Transplantation Donors, Based on The Turkish Liver Transplant Registry  
Zeki Karasu, Izmir, Turkey

P-282  Outcome of Living Donor Liver Transplantation between Genetically Related and Unrelated Donors: Experience of 1206 Adult Living Donor Liver Transplantations from a Single Centre  
Neeraj Saraf, Gurgaon, India

P-283  Impact on Patient Outcome after Live Donor Liver Transplantation Using Grafts with ≥2 Bile Ducts  
Dagmar Kollmann, Vienna, Austria

P-284  Single-center Experience of ABO-Incompatible Living Donor Liver Transplantation with a Simplified Desensitization Protocol  
Dong Lak Choi, Daegu, Korea, Republic of

P-285  Outcomes of Living and Deceased Donor Liver Transplant Recipients According to the MELD Score  
Deok Gie Kim, Seoul, Korea, Republic of

P-286  Living Donor Liver Transplantation across ABO Blood Group Barrier in Infantile End-stage Liver Diseases  
Bijun Qiu, Shanghai, China

P-287  Portal Vein Arterialization with Roux-en-Y Bilioenteric Anastomosis - A Rescue Technique for Hepatic Artery Thrombosis after Live Donor Liver Transplantation  
Sujeet Saha, Gurgaon, India

P-288  Heterozygous Factor V Leiden Mutation Donors: Is it Justified to Reject them?  
Iman Montasser, Cairo, Egypt
Scientific Programme

P-289  Two Hundred Consecutive Adult Elective Live Donor Liver Transplant for End Stage Liver Disease in a Public Sector Hospital in India
Viniyendra Pamecha, New Delhi, India

P-290  Short Term Life Style Modification Can Improve Fatty Liver in Donor Candidates
Ok-Kyung Kim, Seoul, Korea, Republic of

P-291  Readmission and Reoperation after Living Donor Hepatectomy.
Sorabh Kapoor, Mumbai, India

P-292  Patency of Autologous Portal Vein “Y “Graft Utilised for Anterior Sector Outflow Reconstruction in Adult Living Donor Right Lobe Grafts
Sorabh Kapoor, Mumbai, India

P-293  Estimation of Right Lobe Graft Weight from Computed Tomographic Volumetry for Living Donor Liver Transplantation
Hee Chul Yu, Jeonju-si, Korea, Republic of

Poster Sessions
11:30 - 12:00

Poster Session 2: Malignancies

P-294  Different Prognostic Factors for Early and Late Recurrence after Adult Living Donor Liver Transplantation for Hepatocellular carcinoma
Suk Kyun Hong, Seoul, Korea, Republic of

P-295  Liver Transplantation for Intermediate Stage of HCC
Naoko Kamo, Kyoto, Japan

P-296  Prognostic Significance of Preoperative Neutrophil-lymphocyte Ratio in Patients Undergoing Liver Transplantation with HCC within Milan Criteria
Su Kyung Kwon, Seoul, Korea, Republic of

P-297  Clinicopathological Features and Prognosis of Hepatic Epithelioid Hemangioendothelioma after Liver Resection and Transplantation
Sumin Ha, Seoul, Korea, Republic of

P-298  Defining Optimal Treatment for Outside Milan Criteria Hepatocellular Carcinoma - A Propensity Score Matched Analysis
KA WING Ma, Hong Kong, Hong Kong

P-299  Synergistic Anticancer Effect of Metformin in Combination with Immunosuppressant on Hepatocellular Carcinoma Cell Lines
Suk-Won Suh, Seoul, Korea, Republic of

P-300  Which Way to Go, Liver Resection or Liver Transplantation for Hepatocellular Carcinoma in Child a Liver Cirrhosis
Kyung Chul Yoon, Seoul, Korea, Republic of

P-301  The Chemotherapy Effects on Tumor Recurrence after Liver Transplantation under Different Liver Transplantation Criteria
Lai Wei, Wuhan, China

P-303  Glypican-3 Based Neural Networking Model for the Diagnosis of Hepatocellular Carcinoma
Xiao Xu, Hangzhou, China
Scientific Programme

P-304  Risk Factors and Recurrence Rate in HCC Liver Transplanted Patients - Single Liver Transplant Centre Experience  
Gabriela Smira, Bucharest, Romania

P-305  Impact of Loco Regional Neoadjuvant Therapy on Recurrence in Patients with Locally Advanced Hepatocellular Carcinoma Undergoing Living Donor Liver Transplantation  
Rahul Roy, Gurugram, India

P-306  Alpha-fetoprotein Level Predicts Recurrence Post Liver Transplant for Hepatocellular Carcinoma  
Poh Seng Tan, Singapore, Singapore

P-307  Early Metastatic Recurrence of Hepatocellular Carcinoma (HCC) in Post-liver Transplant Recipient Treated with Direct Acting Antiviral Therapy, Case Reports: Is It Real or Incidental?  
Ashokkumar Jain, Hershey, United States

P-308  HJURP Might Be a Novel Prognostic Marker for Recurrence of Hepatocellular Carcinoma after Liver Transplantation  
Tianchi Chen, Hangzhou, China

P-309  Clinical Significance of Tumor-associated Carbohydrate Antigen Globo H in Hepatocellular Carcinoma  
Jiunn-Chang Lin, New Taipei, Taiwan, Republic of China

Poster Sessions  
11:30 - 12:00

Poster Session 2: Outcomes

P-310  Early Liver Allograft Failure due to Severe Cholestasis of Unknown Aetiology - A Diagnostic Dilemma?  
Roberta Angelico, Rome, Italy

P-311  Patients Eligible for Regional Organ Sharing Achieve Excellent Survival and Performance Outcomes Despite Extra Postoperative Resource Utilization  
David Victor, Houston, United States

P-312  Clinical Outcomes of Re-transplantation: A Single-center Experience  
Yong-Woon Kim, Seoul, Korea, Republic of

P-313  Histologically Proven Non-alcoholic Fatty Liver and Clinically Related Factors in Recipients after Liver Transplantation  
Youngjin Yoon, Seoul, Korea, Republic of

P-314  Frequency and Outcome of Type 2 Diabetes Mellitus in Liver Transplant Candidates in the United States  
Qiang Zhao, Guangzhou, China

P-315  Clinical Significance of Lactate Clearance for Development of Early Allograft Dysfunction and Short Term Prognosis in Liver Recipients  
Deok Gie Kim, Seoul, Korea, Republic of

P-316  Chronic Non Tumoural Portal Vein Thrombosis Does Not Adversely Impact Outcome after Living Donor Liver Transplantation  
Neeraj Saraf, Gurgaon, India
Scientific Programme

P-317  Sarcopenia Affects the Diagnosis of Renal Impairment after Orthotopic Liver Transplantation  
Sabine Zitta, Graz, Austria

P-318  Is DCD Graft an Additional Mortality Risk Factor in Nash Recipients?  
Irene Scalera, Birmingham, United Kingdom

P-319  Endoscopic Management of Post-liver Transplant Biliary Complications: Outcome Analysis of 751 Procedures  
Paolo De Simone, Pisa, Italy

P-320  Avoiding Futility: Outcomes of Liver Transplantation in Critically Ill Patients over 2 Decades  
Tiffany CL Wong, Hong Kong, Hong Kong

P-321  Postoperative Treatment with CMV-hyperimmunoglobulin Reduces Early Infectious and Immunologic Complications in Critically Ill High MELD (≥ 30) Liver Recipients  
Arno Kornberg, Munich, Germany

P-322  Impact of Intraoperative Blood Transfusion on Outcome in Infants Undergoing Orthotopic Liver Transplantation  
Selvakumar Malleeswaran, Chennai, India

P-323  Bacterial DNA in Blood Is an Independent Risk Factor for Readmission and Change of Immunosuppression at One Year in Liver Transplant Recipients  
Gonzalo Rodríguez Laiz, Alicante, Spain

P-324  Against the Clock: Speed in Contemporary Liver Transplantation  
Paolo Muiesan, Birmingham, United Kingdom

P-325  Recipient Comorbidities and Frailty at Liver Transplantation Prove Better Predictors of Liver Transplant Futility than MELD  
Julius Balogh, Houston, United States

P-326  Tropomyosin-4 Promotes the Recurrence of Hepatocellular Carcinoma via Regulating Epithelial-mesenchymal Transition after Liver Transplantation  
Liming Wu, Hangzhou, China

P-327  The Type of Ventral Incisional Hernia Repair Alters Health Related Quality of Life of Liver Transplant Recipients  
Daniela Kniepeiss, Graz, Austria

P-328  Influence of HCV-cirrhosis on Receptors of Maastricht Type II Donors after Cardiac Death (DCD)  
Anisa Nutu, Madrid, Spain

P-329  Donors after Cardiac Death (DCD) Maastricht Type II. Our Experience  
Maria García-Conde, Madrid, Spain

P-330  Leptin-associated Single Nucleotide Polymorphism Contributes to the Prognosis of the Patients after Liver Transplantation  
Chen Junjie, Hangzhou, China

P-331  Assessment and Predictive Factors of Medication Adherence among Liver Transplant Recipients at a Tertiary Hospital in South Korea  
Ki-Soo Lim, Seoungnam, Korea, Republic of
Scientific Programme

P-332  Liver Transplantation and Auxiliary Partial Orthotopic Transplantation Outcomes in Wilson’s Disease: Results of a Single Center
Mehmet Haberal, Ankara, Turkey

P-333  The Results of Arterial Vascular Reconstruction on Back-table in Liver Transplantation
Halit Ziya Dundar, Bursa, Turkey

Tom K Gallagher, Chicago, United States

P-335  Redo-Orthotopic Liver Transplant Outcomes in High MELD Recipients
Maha Boktour, Houston, United States

P-336  Retransplantation after Living Donor Living Transplantation
Hillary Braun, San Francisco, United States

P-337  Pattern & Impact of Readmissions following Deceased & Live Donor Liver Transplantation
Ashwin Rammohan, Chennai, India

P-338  Factors Predicting Readmission Following Deceased and Live Donor Liver Transplantation
Ashwin Rammohan, Chennai, India

P-339  Failure of Endoscopy for Nonanastomotic Biliary Strictures after Liver Transplantation
Paolo De Simone, Pisa, Italy

P-340  Age No Bar in Living Donor Liver Transplant Results of Long Term Outcome in Septuagenarians from a Single Centre
Karthik Mathivanan, Gurgaon, India

P-341  Liver Retransplantation - Single Centre Experience
Hannah Esser, Innsbruck, Austria

P-342  Is there any Difference between ABO-incompatible and ABO-compatible Liver Transplantation? Oncologic Aspect
Deok Gie Kim, Seoul, Korea, Republic of

P-343  Preoperative Short-term Fasting Improves Clinical Outcomes and Attenuates Inflammatory Response and Oxidative Stress in Patients Undergoing Hepatectomy
Jianhua Rao, Nanjing, China

P-344  Transarterial Chemoembolization (TACE) Prior to Liver Transplantation: Does it Add to Surgical Risk when Considering Marginal Grafts?
Amanda Carvalheiro, Birmingham, United Kingdom

P-345  Current Analysis on Employment Status of Recipients after Living or Deceased Donor Liver Transplantation
So Hyun Kang, Seongnam, Korea, Republic of

P-346  Surgical Volume: How to Negate its Effect on Outcome?
Sumana Kolar Ramachandran, Bangalore, India

Poster Sessions
11:30 - 12:00

Poster Session 2: Patient Selection / Organ Allocation / Organ Recovery
Scientific Programme

P-347 Concurrent Psychosocial Variables Confound Perioperative and Postoperative Care in Liver Transplant Recipients with Alcoholic Liver Disease
Samuel Sultan, Baltimore, United States

P-348 Analysis of Short-term Changes in Deceased Donor Liver Allocation and Transplantation According to New Application of MELD System in a Korean High-volume Center
In Ok Kim, Seoul, Korea, Republic of

P-349 Sex, Height, and Region Are Key Determinants of Probability of Liver Transplant (LT) among Patients with Hepatocellular Carcinoma (HCC)
Monika Sarkar, San Francisco, United States

P-350 Inequity in Graft Access and Untimely Re-transplantation of Late Hepatic Artery Thrombosis Patients Lead to Inferior Outcomes
Paolo Muiesan, Birmingham, United Kingdom

P-351 Warm Dissection during Liver Procurement for Donation after Brain Death (DBD): Superior Outcomes with Multi-modular Training
Mauro Enrique Tun-Abraham, London, Canada

P-352 Optimized Rat Models of Donation after Cardiac Death for Bench to Bed Translation
Jianhui Li, Hangzhou, China

P-353 A Novel Learning Algorithm to Predict Individual Survival Time after Liver Transplantation for Primary Sclerosing Cholangitis
Axel Andres, Geneva, Switzerland

P-354 Factors Influencing the Immediate Post-operative Outcomes Following Split and Whole Liver Transplant Surgery
Catherine Stretton, Edinburgh, United Kingdom

P-356 An Effective Model for Predicting Early Allograft Dysfunction in Liver Transplantation with Donation after Cardiac Death
Xiao Xu, Hangzhou, China

P-357 The Pediatric Liver Donor Pool has Decreased Due to a Decline in Motor Vehicle Deaths in the United States
Dor Yoeli, Houston, United States

P-358 Comparison between Subnormothermic Machine Perfusion and Normothermic Machine Perfusion in Human Donor Liver Preservation
Jixuan Duan, Hangzhou, China

P-359 Better than Expected Long-term Outcomes of Liver-kidney Transplantation Using Donation after Cardiac Death Donors
John LaMattina, Baltimore, United States

Poster Session 2: Pediatrics

P-360 Are Multiple Arteries Precluding Pediatric Domino Liver Transplantation in Maple Syrup Urine Disease?
Roberta Angelico, Rome, Italy
Scientific Programme

P-361  Duct to Duct versus Bilio-enteric Anastomosis for Biliary Reconstruction in Paediatric Living Donor Liver Transplantation
Rahul Roy, Gurugram, India

P-362  Single Experience of Combined Liver and Kidney Organ Harvesting from Children Donor in China
Deng Feiwen, Foshan, China

P-363  Outcomes Following Living Donor Liver Transplantation for Infants Younger than 1 Year of Age: Higher Morbidity, Similar Survival
Qin Yi Lee, Singapore, Singapore

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 2: Radiology

P-364  Hepatic Arterial Hypoperfusion Syndrome: Report of Two Cases
Elvan Onur Kırımker, Ankara, Turkey

P-365  Dual Stent Placement for Suprahepatic Inferior Vena Cava Stenosis after Deceased Donor Liver Transplantation with Piggy-back Technique
Tae-Seok Kim, Daegu, Korea, Republic of

P-366  Successful Recanalization of Extrahepatic Portal Vein Occlusion in a Child
Dor Yoeli, Houston, United States

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 2: Recurrent Disease / Pathology

P-367  Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Yongkyu Chung, Seoul, Korea, Republic of

P-368  Biochemical Deterioration and Histological Changes Post-liver Transplant (LTx) HCV-positive Patients after Direct Acting Antiviral Therapy (DAA) with Sustained Virological Response (SVR): Possible Causes and Management
Ashokkumar Jain, Hershey, United States

P-369  No Association between Single Nucleotide Polymorphism of One-carbon Metabolism Genes and Cancer Recurrence after Liver Transplantation
Chao Wang, Hangzhou, China

P-370  Plasmapheresis as an Effective Rescue Therapy in a Case of Intrahepatic Cholestasis Disease Secondary to ATP8B1 Deficiency
Enrique Rodríguez de Santiago, Madrid, Spain
Poster Session 2: Surgical Techniques / Complications

P-371 “Non Touch” Thoracic Inferior Vena Cava Technique as an Improvement in Combined Lung and Abdominal Organs Procurement in Donation after Circulatory Death Donors Mastrich III
Mireia Caralt, Barcelona, Spain

P-372 Early Bile Leakage Following Orthotopic Liver Transplantation
Hannah Esser, Innsbruck, Austria

P-373 New Technique of Ductoplasty in Multiple Duct Setting - A Simple and Effective Method
Suresh Reddy, Delhi, India

P-374 Biliary Complication after Pediatric Liver Transplantation: Incidence, Risk Factors, Management, and Outcome, a 15-year Single Center Experience of 134 Patients
Chih-Yang Hsiao, Taipei, Taiwan, Republic of China

P-375 Partial Splenectomy to Prevent Intractable Hypersplenism after Pediatric Liver Transplantation
Lin Wei, Beijing, China

P-376 Intraoperative Measurements of Hepatic Artery and Portal Vein Blood Flow during Liver Transplantation: An Effective Way to Predict Graft Function
Louise Barbier, Chambray-les-Tours, France

P-377 Adult Living Donor Liver Transplantation using Right Lobe without Middle Hepatic Vein after Hepatic Venoplasty with Ringed Polytetrafluoroethylene Vascular Grafts
Beicheng Sun, Nanjing, China

P-378 Intraoperative Portal Pressure Measurement is Important Guidance for Portal Flow Modulation During Living Donor Liver Transplantation
Ting Lung Lin, Kaohsiung, Taiwan, Republic of China

P-379 Ex-vivo Organ Perfusion Technique for Deceased Donor Liver Transplantation (DDLT)
Amit Rastogi, Gurugram, India

P-380 Single Incision for Combined Liver Kidney Transplant: Keeping the Kidney in the Retroperitoneal Space
Felipe Mello, Rio de Janeiro, Brazil

P-381 Complications Requiring Reoperation after Pediatric Liver Transplantation
Dor Yoeli, Houston, United States

P-382 Endoscopy vs Surgery for the Treatment of Anastomotic Biliary Stricture Following Deceased Donor Liver Transplantation
Laura Lladó, Barcelona, Spain

P-383 A New Technique to Overcome Hepatic Outflow Obstruction (HVOO) in Living Liver Transplantation
Hüseyin Kerem Tolan, Istanbul, Turkey

P-384 Dangerous Choice; PTFE Graft for Hepatic Vein Reconstruction in LDLT
Hyoung Tae Kim, Daegu, Korea, Republic of

P-385 Modified Back-wall First Artery Anastomosis Technique in Living Donor Liver Transplantation
Sacit Coban, Gaziantep, Turkey
Scientific Programme

P-386  Cystic Duct Usage for Biliary Reconstruction in Living Related Right Lobe Liver Transplantation in Case of Extrahepatic Abberant Right Posterior Ductus Presence
Ayhan Dinckan, Istanbul, Turkey

P-387  Hepatic Artery Thrombosis in Living Donor Liver Transplantation-looking beyond Re-transplantation
Divakar Jain, Noida, India

P-388  Evaluation of Early and Late Effects of the Surgical Treatment of Early Hepatic Artery Thrombosis after Liver Transplantation
Jacek Pawlicki, Katowice, Poland

P-389  Use of Acellular Bovine Pericardium Patch for Reconstruction of Inferior Vena Cava in LDLT
Gurkan Ozturk, Erzurum, Turkey

P-390  Relationship among Cytokines, Human Leukocyte Antigen (HLA) Compatibility and Graft-versus-Host Disease (GVHD) after Liver Transplantation
Xueqin Meng, Hangzhou, China

P-391  Higher PMPM Score is Associated with Acute Rejection after Living Donor Liver Transplantation
Qiang Wei, Hangzhou, China

P-392  Nursing Care of Digestive Tract Functional Recovery after Modified Abdominal Multiple Organ Transplantation
Xinchun Luo, Guangzhou, China

P-393  How Can we Treat Acute Graft versus Host Disease after Liver Transplantation? 2 Case Reports
SUNG-HWA Kang, Busan, Korea, Republic of

P-394  Modifying Vascular Segmentations between Donor Pancreas and Liver to Improve Transplant Surgical Techniques (Report of 11 Cases)
Anbin Hu, Guangzhou, China

P-395  Incidence and Outcomes of Re-explorations in Living Donor Liver Transplantation
Vibha Varma, Mumbai, India

P-396  Heterotopic Auxiliary Liver Transplantation(ALTx) - Revisited
Varvara Kirchner, Minneapolis, United States

P-397  New Technologies of the Orthotopic Liver Transplantation and Living Donor Liver Transplantation
Sergey Voskanyan, Moscow, Russian Federation

P-398  Severe Delayed Hemolysis Post Liver Transplantation Caused by Anti-mur Antibodies
Quan Zhuang, Changsha, China

P-399  Gastrointestinal Perforation after Liver Transplantation in Pediatric Patients
Mehmet Haberal, Ankara, Turkey

P-400  Risk Factors for Biliary Stones after Donor Brain Dead Liver Transplantation
Umberto Maggi, Milano, Italy
Scientific Programme

Poster Sessions
11:30 - 12:00

Poster Session 2: Hepatitis B/C

P-252  Treatment of Hepatitis C Virus After Liver Transplantation: Assessing Optimal Treatment Time
       Bharath Ravichandran, Baltimore, United States

P-253  Evaluation of Antiviral Therapy with or without Hepatitis B Immunoglobulin for Prevention of Hepatitis B Recurrence in Liver Transplant Recipients: Experience in a Transplant Centre
       Andrea Santos, Campinas, Brazil

P-254  Results of Treatment of Post-transplant Hepatitis C in a Brazilian Liver Transplant Center in the Era of Direct Antiviral Agents
       Bianca Della Guardia, São Paulo, Brazil

P-255  The Safety and Efficacy of Directly-acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-analysis
       Zhiyong Guo, Guangzhou, China

P-256  Daclatasvir-sofosbuvir with or without Ribavirin in Liver Transplant Recipients: A Single-center Experience
       Marcos Mucenic, Porto Alegre, Brazil

Poster Sessions
11:30 - 12:00

Poster Session 2: Late breaking posters

LB P-1  Utility of iCP Bolt in ALF Secondary to Paracetamol Overdose: A Tertiary UK Centre Experience over a Decade
        Krishna Rao, Leeds, United Kingdom

LB P-2  Influence of Preoperative Inteleukin-6 levels on Postoperative Graft Regeneration in Living Donor Liver Transplantation
        Min Suk Chae, Seoul, Korea, Republic of

LB P-3  Predictive Role of Intraoperative Plasma Fibrinogen for Postoperative Portal Venous Flow in Living Donor Liver Transplantation
        Min Suk Chae, Seoul, Korea, Republic of

LB P-4  Role of Ultrasound Guided Rectus Sheath & Transversus Abdominis Plane Block in Fast Tracking Pediatric Patients Undergoing Liver Transplantation
        Vijay Shankar, New Delhi, India

LB P-5  A Different Approach to the Anaesthetic Management of a Patient with High MELD Score Who Underwent Live Donor Liver Transplant (LDLT) - A Case Report
        Tanuja Mallik, Delhi NCR, India

LB P-6  Intravenous Milrinone for Controlled Low Central Venous Pressure among Liver Surgeries: An Early Impression
        Kai Inn Lim, Singapore, Singapore

LB P-7  Electrolyte Changes Associated with Pre-Infusion Washing of Bank Blood with The Hemonetics Cell Saver V® During Liver Transplantation
        Anand Puttappa, Cambridge, United Kingdom
Scientific Programme

LB P-8  Intraoperative Alkalizing Agents During Liver Transplantation: Does It Matter for Outcomes?  
Jana Hudcova, Burlington, United States

LB P-9  Anesthetic Management of Liver Transplantation in A Patient with History of CABG with Very Low Ejection Fraction  
Sachin Kumar, New Delhi, India

LB P-10  How Small Can We Go in Liver Transplantation? GRWR 0.44  
Ashish Malik, New Delhi, India

LB P-11  Living Donor Liver Transplantation in a Patient with Myasthenia Gravis: Case Report  
Umut Acar, Istanbul, Turkey

LB P-12  A Diagnostic Challenge in a Deteriorating Patient with Aortic Stenosis after Liver Transplantation  
Victoria McMullan, Dublin, Ireland

LB P-13  Isoglycyrrhizinate Magnesium Plus FK506 Reduces Hepatic Ischemia-Reperfusion Injury through HMGB1 Inhibition in a Rat Model of Liver Transplantation  
Yuanxing Liu, Hangzhou, China

LB P-14  Interpretation of Legal Issues Concerning Organ Utilization from HBV Infected Donors  
Jaroslaw Czerwinski, Warsaw, Poland

LB P-15  LIVE-C-FREE: Interim Results of A Prospective, Randomized Trial  
Derek Dubay, Charleston, United States

LB P-16  Real World Experience of One Year Outcome after Treating Hepatitis C Virus Post Liver and Liver/Kidney Transplant Patients Using Direct Acting Antivirals: Single Center Experience  
Khaled Selim, Loma Linda, United States

LB P-17  Real World Experience of One Year Outcome after Treating Hepatitis C in Patients with Decompensated Cirrhosis Using Direct Acting Antivirals in Liver Transplant Setting  
Khaled Selim, Loma Linda, United States

LB P-18  Randomized Clinical Trial: Efficacy and Safety of Different Calcineurin Inhibitor Reductions Combined with Mycophenolate Mofetil in Liver Transplant Patients with Chronic Renal Dysfunction  
Lin Zhong, Shanghai, China

LB P-19  Efficacy and Safety of Everolimus with Reduced Tacrolimus in Living-Donor Liver Transplant (LDLT) Recipients with Hepatocellular Carcinoma: Subgroup Analysis from the H2307 Study  
Patricia Lopez, Basel, Switzerland

LB P-20  Everolimus with Reduced Tacrolimus (EVR/rTAC) Maintains Efficacy Following Living Donor Liver Transplantation (LDLT): An International Randomized Trial  
Patricia Lopez, Basel, Switzerland

LB P-21  Donors‘CYP3A5 and Recipients‘CYP3A4 and TBL Predict Tacrolimus Disposition and New-Onset Hypertension in Liver Transplant Patients  
Yuan Liu, Shanghai, China

LB P-22  Association between FMO3 and ABC1 and Cholesterol Level and the Risk of New-Onset Hypertension after Liver Transplantation  
Junwei Fan, Shanghai, China
Scientific Programme

LB P-23  Comparative Study of Pure Laparoscopic Living Donor Right Hepatectomy Versus Conventional Open Living Donor Right Hepatectomy
Hwui-Dong Cho, Seoul, Korea, Republic of

LB P-24  Left Lobe LDLT in Adults: A Fair Option in Some Patients
Basant Mahadevappa, Bangalore, India

ILTS/TTS Joint Symposium
12:00 - 13:30  Congress Hall

Avoiding and managing cholangiopathy in DCD

Chairs:
Nancy Ascher, San Francisco, United States
Michael R. Charlton, Chicago, United States

Risk factors for ischemic-type biliary lesions  12:00
Peter L. Abt, Philadelphia, United States

Flushing the bile ducts and pumping the liver  12:20
Paolo Muiesan, Birmingham, United Kingdom

Renal failure post DCD liver transplant  12:40
Wojciech Polak, Rotterdam, Netherlands

How to encourage organ utilization  13:00
Constantino Fondevilla, Barcelona, Spain

Featured Symposium
12:00 - 13:30  Meeting Hall 1

Surviving acute on chronic liver failure

Chairs:
Faouzi Saliba, Villejuif, France
Geraldine Diaz, Chicago, United States

The concept and the challenge  12:00
Rajiv Jalan, London, United Kingdom

Sepsis - an always present threat  12:20
Fuat Saner, Essen, Germany

ICU management  12:40
Constantine Karvellas, Edmonton, Canada

When to transplant, when not to transplant  13:00
Pavel Trunečka, Prague, Czech Republic
Featured Symposium
12:00 - 13:30
Meeting Hall 4

**What’s new in basic science?**

**Chairs:**
Michael Olausson, Göteborg, Sweden

- **Xenotransplantation as bridge to allo transplantation**
  Burcin Ekser, Indianapolis, United States

- **Organ engineering**
  Pedro Baptista, Zaragoza, Spain

- **Preventing ischemic injury: cooling the donor/preconditioning/warm perfusion**
  Claus Niemann, San Francisco, United States

- **AB0i LT - What graft, which protocol, future perspectives**
  William Bennet, Gothenburg, Sweden

---

Featured Symposium
12:00 - 13:30
Meeting Hall 5

**Can we do more for pediatric transplantation?**

**Chairs:**
Jacques Pirenne, Leuven, Belgium
Nigel Heaton, London, United Kingdom

- **Split LT: Techniques & pitfalls**
  Jiří Froněk, Prague, Czech Republic

- **Optimising a high-risk pediatric recipient**
  Anil Dhawan, London, United Kingdom

- **Late graft failure after Pediatric LT, causes and prevention**
  Michele Colledan, Bergamo, Italy

- **Liver transplantation for metabolic liver disease**
  Mohamed Rela, Chennai, India

---

Sponsored Lunch Symposium
13:30 - 15:00
Forum Hall

**Sponsored Lunch Symposium**

For more details, please visit the [2017 Joint International Congress of ILTS, ELITA & LICAGE website](http://2017.ilts.org/industry-program/industry-symposium.html)
Scientific Programme

State of the art lecture
15:00 - 15:30

State-of-the-Art Lecture 1

Chairs:
Michael R. Charlton, Chicago, United States

Rules in liver transplantation
James Neuberger, Birmingham, United Kingdom

Concurrent (LICAGE)
15:30 - 17:00

Anesthesia & Critical Care: news from the world

Chairs:
Fuat Saner, Essen, Germany
Eva Kieslichová, Praha, Czech Republic

O-14 Kinetics of Hemostasis Reserve Capacity in Bloodless Liver Transplantation
Timea Rengeiné Kiss, Budapest, Hungary
15:30

O-15 Reliability of Point-of-Care Hematocrit Measurement during Liver Transplantation
15:40

O-16 Effect of Bacterial Translocation on Hemodynamic and Coagulation Parameters during Liver Transplantation
Ahmed Mukhtar, Cairo, Egypt
15:50

O-17 Incidence and Risk Factors for Death from Intracardiac Clot and Pulmonary Embolism (ICC/PE) during and Immediately Following Orthotopic Liver Transplantation (OLT)
Kyota Fukazawa, Seattle, United States
16:00

O-18 The Effect of Hypertrophic Cardiomyopathy on Mortality in Liver Transplantation
Sher-Lu Pai, Jacksonville, United States
16:10

O-19 Postoperative Myocardial Injury in Liver Transplant Patients: A Single Center Pilot Study
Christopher Wray, Los Angeles, United States
16:20

O-20 Experience with the First 10 Cases of Normothermic Machine Preservation in Human Liver Transplantation - Comparison of Matched Cohort
Jacek Cywinski, Cleveland, United States
16:30

O-21 The Effect of Obesity over the Development of Acute Kidney Injury (AKI) in Patients Undergoing Live Donor Liver Transplantation (LDLT)-prospective Observational Study
16:40

O-22 Locoregional Anesthesia Is Associated with Reduced Complications in Patient with Cirrhosis Undergoing Open Inguinal Hernia Repair
Zachary Dietch, Charlottesville, United States
16:50
The 2017 Joint International Congress of ILTS, ELITA & LICAGE  
May 24 - 27, 2017,  
Prague, Czech Republic

Scientific Programme

Concurrent Oral Abstract Session  
15:30 - 17:00

Meeting Hall 1

Acute liver failure

Chairs:  
William Bernal, London, United Kingdom  
Didier Samuel, Paris, France

O-29  
**Acute Liver Failure in Porcine Hepatectomy Model**  
Harvey Chen, Rochester, United States  
15:30

O-24  
**Acute Liver Failure Treated with MARS: Access to Liver Transplantation and Hospital Survival - Result of a Retrospective Multicenter Study in France, 2004-2008**  
Christophe Camus, Rennes, France  
15:40

O-25  
**The Impact of Continuous Renal Replacement Therapy on Serum Ammonia Concentrations in Acute Liver Failure: A Multicenter Cohort Study**  
Constantine Karvellas, Edmonton, Canada  
15:50

O-26  
**Development and Validation of an FLF-transplant Score to Predict Mortality of Patients with Fulminant Liver Failure**  
Zhiyong Guo, Guangzhou, China  
16:00

O-27  
**The Role of Steroids Therapy and Liver Transplantation in Acute Severe Autoimmune Hepatitis**  
Eleonora De Martin, Villejuif, France  
16:10

O-28  
**Auxiliary Partial Orthotopic Liver Transplantation (APOLT): No Longer Stepping through the Looking Glass?**  
Ashwin Rammohan, Chennai, India  
16:20

O-23  
**Interim Analysis of Mayo SRBAL in a Pig Model of Post Hepatectomy ALF**  
Harvey Chen, Rochester, United States  
16:30

O-30  
**Liver Transplantation for Acute Liver Failure due to Drug Induced Liver Injury in a Multi-ethnic Asian Population**  
En Xian Sarah Low, Singapore, Singapore  
16:40

O-31  
**Living Donor Liver Transplant for Acute Liver Failure in Pediatric Patients**  
Rommel Sandhyav, New Delhi, India  
16:50

Concurrent Oral Abstract Session  
15:30 - 17:00

Meeting Hall 4

Alloimmunity and graft conditioning

Chairs:  
Matej Kocik, Prague, Czech Republic

O-32  
**Bile Production during Normothermic Machine Perfusion of Human Livers for Transplantation**  
David Nasralla, Oxford, United Kingdom  
15:30
Scientific Programme

O-33  
Impact of STEEN vs Gelofusine as Perfusate during Normothermic ex vivo Liver Perfusion on Outcome of Pig Liver Transplantation
Ivan Linares, Toronto, Canada
15:40

O-34  
The Intestinal-liver Axis of FGF15-FGFR4-PPARα Signal Control Liver Ischemia Reperfusion Injury through Regulating Autophagy
Qiang Zhao, Guangzhou, China
15:50

O-35  
Arterial Perfusion during Liver Machine Preservation: Is it Necessary?
Paulo Martins, Worcester, United States
16:00

O-36  
Phenotypic and Functional Assessment of T Cell Alloimmunity after Liver Transplantation
Timucin Taner, Rochester, United States
16:10

O-37  
Assessment of Graft Metabolism and Function During Normothermic ex vivo Liver Perfusion - Objective Assessment Prior to Transplantation
Juan Echeverri, Toronto, Canada
16:20

O-38  
Activation of AMPK by Metformin Attenuates Marginal Graft Injury via Promoting Mitochondrial Biogenesis
Jiang Liu, Hong Kong, Hong Kong
16:30

O-39  
Bile Duct Strictures and Regeneration: Characterization of Peribiliary Gland-resident Stem Cells Using Organoid Cultures
Monique M.A. Verstegen, Rotterdam, Netherlands
16:40

O-40  
A Proof of Concept for Liver Graft Modification Using Warm Ex vivo Perfusion - “It is not just about rescuing marginal grafts”
Nicolas Goldaracena, Toronto, Canada
16:50

Concurrent Oral Abstract Session
15:30 - 17:00  
Meeting Hall 5

Malignancies - Novel models for prediction and therapeutics

Chairs:
Kelvin KC Ng, Pokfulam, Hong Kong
Valeria Mas, Charlottesville, United States

O-41  
Intention-to-Treat Survival Benefit of Liver Transplantation in Patients with Hepatocellular Cancer
Quirino Lai, Brussels, Belgium
15:30

O-42  
Predictors of Malignancies in Liver Transplantation as Compared to Other Solid Organ Transplantation
Kymberly Watt, Rochester, United States
15:40

O-43  
Graft Quality Integrated Models for Predicting Post-transplant Hepatocellular Carcinoma Recurrence: A National Registry Study
Qi Ling, Hangzhou, China
15:50

O-44  
Liver Transplantation for NASH-related Hepatocellular Carcinoma Offers Comparable Outcomes versus Non-NASH Etiologies of Hepatocellular Carcinoma
Erin Sadler, Toronto, Canada
16:00
Scientific Programme

O-45  Outcome of Live Donor Liver Transplant in Patients with Co-existent or Recently Treated Extrahepatic Malignancies  16:10
Anisha Tiwari, Gurgaon, India

O-46  Risk Assessment by Combining 18F-FDG-PET with Serologic Markers of Tumor Biology Selects Suitable Liver Transplant Patients with Advanced Hepatocellular Carcinoma  16:20
Arno Kornberg, Munich, Germany

O-47  A Simple Prediction Model for Recurrence of Hepatocellular Carcinoma after Liver Transplantation in Patients without Microvascular Invasion  16:30
Federico Piñero, Pilar, Argentina

O-48  Ethnicity and Underlying Disease Are Key Predictors of 10,844 de Novo Malignancies Following Liver Transplantation  16:40
Kymberly Watt, Rochester, United States

O-49  Single-center Experience of Long-term Survival Outcome between Primary Liver Transplantation and Hepatic Resection with Consequent Salvage Transplantation for Hepatocellular Carcinoma within Milan Criteria  16:50
Kelvin K. Ng, Hong Kong, Hong Kong

Poster Sessions
17:00 - 17:30
Poster Area

Surgical Video Presentations Session 2

eP-5  High Dorsal Isolated Caudate Lobectomy for Hepatocellular Carcinoma  17:00
Xiangcheng Li, Nanjing, China

eP-6  Complex Reconstruction and Innovative Implantation Techniques in LDLT  17:10
Thiagarajan Srinivasan, Gurgaon, India

eP-7  Total Laparoscopic Living Donor Right Hemihepatectomy: First Case in China Mainland  17:20
Hongyu Li, Chengdu, China

Concurrent Oral Abstract Session
17:30 - 19:00
Forum Hall

Technical Progress in Liver Transplant

Chairs:
Vanessa De Villa, Pasig City, Philippines
Jiří Froněk, Prague, Czech Republic

O-50  Impact of Liver Reperfusion Sequences on Outcomes of Liver Transplantation  17:30
Rauf Shahbazov, Charlottesville, United States

O-51  Outcomes in Liver Transplant of Arterial Reconstruction on the Recipient’s Splenic Artery due to Inadequacy of the Hepatic Artery. Experience after 1500 Liver Transplants  17:40
Dra Lladó, Barcelona, Spain
The 2017 Joint International Congress of ILTS, ELITA & LICAGE
May 24 - 27, 2017,
Prague, Czech Republic

Scientific Programme

O-52 Right Lobe Live Liver Donation, Middle Hepatic Vein (MHV) or No MHV - Tailored Approach
Sanjay Goja, Gurgaon, India

O-53 In Situ Split Liver Transplantation for Two Adult Recipients: A Single Center Experience
Dong-Hwan Jung, Seoul, Korea, Republic of

O-54 Domino Cross Auxiliary Liver Transplantation between Different Metabolic Disorders Diseases of the Liver
Zhijun Zhu, Beijing, China

O-55 A Simplified Multivisceral Transplantation Procedure for Patients with Combined End-stage Liver Disease and Type 2 Diabetes Mellitus
Xiao-Shun He, Guangzhou, China

O-56 Salvage living Donor Liver Transplantation for Recurrent Hepatocellular Carcinoma after Prior Laparoscopic Hepatectomy in a Single Institute
Seok-Hwan Kim, Seoul, Korea, Republic of

O-57 Efficacy of Octreotide to Treat Massive Ascites after Living Donor Liver Transplantation
YiChia Chan, Kaohsiung, Taiwan, Republic of China

O-58 Development and Validation of a Nomogram to Predict Primary Non-function in Liver Transplantation from Donation after Cardiac Death Donors
Zhiyong Guo, Guangzhou, China

Concurrent Oral Abstract Session
17:30 - 19:00
Meeting Hall 1

Hepatitis B/C

Chairs:
Luca Belli, Milan, Italy
Jan Sperl, Prague, Czech Republic

O-59 Posttransplantation Direct-acting Antivirals Provides a Safe and Effective Treatment without Increase Recurrence of Hepatocellular Carcinoma in HCV-related HCC Patients
Shih Min Yin, Kaohsiung, Taiwan, Republic of China

O-60 Efficacy and Safety of Sofosbuvir Based Regimens for Treatment of Hepatitis C Recurrence after Living Donor Liver Transplantation
Sanjiv Saigal, Gurgaon, India

O-61 The Safety and Tolerability of Sofosbuvir/Velpatasvir with Weight Based Ribavirin in Patients with Child-pugh Class B Cirrhosis in the ASTRAL-4 study
Michael R. Charlton, Chicago, United States

O-62 Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Eradication: Outcome after Delisting. A European Study
Giovanni Perricone, Milano, Italy
Scientific Programme

O-63  Evolution of Waiting List and Liver Transplantation for HCV Related Cirrhosis after Introduction of DAAs Regimens: A Single Center Experience  
Alberto Ferrarese, Padua, Italy  
18:10

O-64  Liver Volume as a Predictor of Outcome after HCV Eradication in Cirrhotic Patients  
18:20

O-65  Secretion of Hepatitis B Surface Antigen from HBV Positive Cells Is Inhibited by HBV Monoclonal Antibody (GC1102)  
Kwang-Woong Lee, Seoul, Korea, Republic of  
18:30

O-66  Benefit of Anti-hepatitis B Immunoglobulin (HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function  
Deok Gie Kim, Seoul, Korea, Republic of  
18:40

O-67  Long-term Clinical Outcomes of Hepatitis B Surface Antibody-negative Recipients from Core Antibody-positive Donors in Pediatric Living Donor Liver Transplantation: A Single-center Experience  
Suk Kyun Hong, Seoul, Korea, Republic of  
18:50

Concurrent Oral Abstract Session  
17:30 - 19:00  
Meeting Hall 4

Immunosuppression

Chairs:  
Paolo De Simone, Pisa, Italy  
Pavel Trunečka, Prague, Czech Republic

O-68  The Imbalanced Host Gut Microbiota of Liver Transplant Recipients Received Immunosuppressive Monotherapy of Tacrolimus  
Shaoyan Xu, Hangzhou, China  
17:30

O-69  Impact of Immunosuppression on the Metagenomic Composition of the Intestinal Microbiome: Implications for Diabetes Post-liver Transplant  
Kymberly Watt, Rochester, United States  
17:40

O-70  Post-liver Transplant Acute Rejection and Hepatocellular Cancer Recurrence: An Untold Story  
Quirino Lai, Brussels, Belgium  
17:50

O-71  Steroid-free Liver Transplantation Using Rabbit ATG (RATG): Report of 1100 Consecutive Cases  
James Eason, Memphis, United States  
18:00

O-72  Delayed Calcineurin Inhibitor Introduction without Antibody Induction to Prevent Acute Renal Failure after Liver Transplantation  
Somchai Limsricharmern, Bangkok, Thailand  
18:10

O-73  Acute Graft-vs-Host Disease after Liver Transplantation: Experience at a High-volume Liver Transplantation Center in Korea  
Woo-Hyoung Kang, Seoul, Korea, Republic of  
18:20

O-74  MiRNA 181a and 148a Plasma Levels during Acute Cellular Rejection in Liver Transplantation  
Pablo Ruiz, Barcelona, Spain  
18:30
### Scientific Programme

<table>
<thead>
<tr>
<th>O-75</th>
<th>Prevalence and Significance of Antibody Mediated Rejection in a Multi-ethnic Asian Liver Transplant Population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mark Muthiah, Singapore, Singapore</td>
</tr>
<tr>
<td>O-76</td>
<td>Incidental Bone Marrow Transplantation Leading to Liver Allograft Tolerance Following Successful Treatment of Graft-versus-Host Disease after Liver Transplantation</td>
</tr>
<tr>
<td></td>
<td>Dong-Sik Kim, Seoul, Korea, Republic of</td>
</tr>
</tbody>
</table>

**Concurrent Oral Abstract Session**
17:30 - 19:00 Meeting Hall 5

**Extended Criteria Donors - Risk Factors and their prevention**

**Chairs:**
Umberto Cillo, Padua, Italy
Wojciech Polak, Rotterdam, Netherlands

<table>
<thead>
<tr>
<th>O-77</th>
<th>Is Ischemic Cholangiopathy in DCD, due to Donor Graft, Recipient Selection or Something Else?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Roberto Hernandez-Alejandro, Rochester, United States</td>
</tr>
<tr>
<td>O-78</td>
<td>The Surgical Approach towards a Liver Procurement from Donors after Circulatory Death Type 3: Results of an Online Survey in Europe</td>
</tr>
<tr>
<td></td>
<td>Marjolein van Reeven, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>O-79</td>
<td>Bacterial Translocation after Liver Transplantation is Associated with Biliary Complications</td>
</tr>
<tr>
<td></td>
<td>Jasmijn Selten, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>O-80</td>
<td>Normothermic Perfusion of Steatotic Human Liver-primary Experiences</td>
</tr>
<tr>
<td></td>
<td>Qiyi Zhang, Hangzhou, China</td>
</tr>
<tr>
<td>O-81</td>
<td>Hypothermic Oxygenated Machine Perfusion Reduces Biliary Reperfusion Injury after Transplantation of Donation after Circulatory Death Livers</td>
</tr>
<tr>
<td></td>
<td>Otto van Leeuwen, Groningen, Netherlands</td>
</tr>
<tr>
<td>O-82</td>
<td>The Use of Octogenarian Donors for Liver Transplant</td>
</tr>
<tr>
<td></td>
<td>Giacomo Zanus, Padova, Italy</td>
</tr>
<tr>
<td>O-83</td>
<td>The Era of the New Centurion: Long Term Outcomes of the Octogenarian Liver</td>
</tr>
<tr>
<td></td>
<td>Francia C Díaz, Valencia, Spain</td>
</tr>
<tr>
<td>O-84</td>
<td>Is it Safe to Use DCD Grafts in Recipients with Pre-transplants Portal Vein Thrombosis?</td>
</tr>
<tr>
<td></td>
<td>Irene Scalera, Birmingham, United Kingdom</td>
</tr>
<tr>
<td>O-85</td>
<td>Steatotic Human Livers Show Inferior Function Compared to Non-steatotic Livers during ex-situ Viability Assessment by Oxygenated Machine Perfusion</td>
</tr>
<tr>
<td></td>
<td>Negin Karimian, Boston, United States</td>
</tr>
</tbody>
</table>
Vanguard Reception
18:45 - 19:45

Zoom Restaurant
Scientific Programme

Friday, 26 May 2017

Vanguard Sessions
06:30 - 08:00
Panorama Hall

Vanguard Debates

Chairs:
Jeron Zerillo, New York, United States
Josh Levitsky, Chicago, United States

PRO mTOR Inhibitors Should Be Used As Post-Liver Transplant Immunosuppression To Prevent Cancer Recurrence
David Victor, Houston, United States

06:30

CON mTOR Inhibitors Should Be Used As Post-Liver Transplant Immunosuppression To Prevent Cancer Recurrence
Jeremy Rajanayagam, Melbourne, Australia

06:45

PRO Living Donor Liver Transplantation For Metastatic Colorectal Cancer
Prashant Bhangui, Medanta, India

07:00

CON Living Donor Liver Transplantation For Metastatic Colorectal Cancer
Alessandro Vitale, Padova, Italy

07:15

PRO Bariatric Surgery Should Be Part Of The Routine Pre-Transplant Evaluation
Alan Contreras, Mexico, Mexico

07:30

CON Bariatric Surgery Should Be Part Of The Routine Pre-Transplant Evaluation
Varvara Kirchner, Minneapolis, United States

07:45

Plenary Abstract Session
08:00 - 09:30
Congress Hall

Plenary Abstract Session 2

Chairs:
Elizabeth Pomfret, Denver, United States
Pavel Trunečka, Prague, Czech Republic

O-86 Bridging to Liver Transplantation: Save your Artery
Dimitri Sneiders, Rotterdam, Netherlands

08:00

Can we Define Futility in Critically Ill Cirrhotic Patients in Intensive Care Units Using the CLIF-C ACLF Score? A European and North American Pooled Analysis
Constantine Karvellas, Edmonton, Canada

08:12

The UK-DCD-Risk-Score - A New proposal to Define Futility in DCD Liver Transplantation
Andrea Schlegel, Birmingham, United Kingdom

08:24
The 2017 Joint International Congress of ILTS, ELITA & LICAGE  
May 24 - 27, 2017,  
Prague, Czech Republic

### Scientific Programme

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-89</td>
<td>Targeted Metabolomic Study of Functional Liver Recovery Post Living Donor Hepatectomy</td>
<td>08:36</td>
<td>Giuliano Testa, Dallas, United States</td>
<td></td>
</tr>
<tr>
<td>O-90</td>
<td>Weight Loss Surgery in Morbidly Obese Patients Awaiting Liver Transplantation: A Single-center Experience</td>
<td>08:48</td>
<td>Suzanne Sharpton, San Francisco, United States</td>
<td></td>
</tr>
<tr>
<td>O-91</td>
<td>Donor CYP3A5 Genotypes and GRWR Impact Pharmacological Effects of Tacrolimus after Pediatric Living Donor Liver Transplantation</td>
<td>09:00</td>
<td>Ping Wan, Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>O-92</td>
<td>Management of Complex Biliary Complications after Live Donor Liver Transplantation with Combined PTBD and Endoscopic Intervention - A Large Volume Center Experience</td>
<td>09:12</td>
<td>Anisha Tiwari, Gurgaon, India</td>
<td></td>
</tr>
</tbody>
</table>

**Presidential Address**

09:30 - 10:30  
**Congress Hall**

**President Address, Distinguished Service Award**

09:30 - 10:30  
**Congress Hall**

**ILTS Business Meeting**

11:00 - 11:30  
**Congress Hall**

**State-of-the-Art Lecture 2**

**Chairs:**
Nancy Kwan Man, Hong Kong, Hong Kong

*Cell transplantation*  
Markus Grompe, Portland, United States

**Poster Sessions**

11:30 - 12:00  
**Poster Area**

**Poster Session 3: Acute Liver Failure**

**P-401**  
Early Allograft Dysfunction in Patients Receiving Donation after Cardiac Death Liver Transplantation  
Fei Sun, Hangzhou, China
The 2017 Joint International Congress of ILTS, ELITA & LICAGE
May 24 - 27, 2017,
Prague, Czech Republic

Scientific Programme

P-402 The Summary Outcome of Liver Transplant for Patients with Liver Failure Using Liver Donated after the Citizen’s Death in a Single Center in China
Deng Feiwen, Foshan, China

P-403 Living Donor Liver Transplantation for Fulminant Liver Failure in a Patient with Multiple Sclerosis Treated with Interferon Beta
Iman Montasser, Cairo, Egypt

P-404 Hepatic Encephalopathy and its Implication to Anesthesia for Liver Transplantation for Acute Liver Failure
Mitsuru Nakatsuka, Richmond, United States

Poster Session 3: Anesthesia / Critical Care Medicine

Poster Sessions
11:30 - 12:00
Poster Area

P-405 Fast Tracking in Liver Transplant Recipients - The Norm Rather than Exception
G V Premkumar, Secunderabad, India

P-406 Correlation of Radial to Femoral Artery Pressures during Reperfusion in Liver Transplantation
Lakshmi Kumar, Kochi, India

P-407 Intensive Care Unit Stay after Living Donor Liver Transplantation: Is Early Transfer to the Surgical Ward Feasible?
Tomomi Ueda, Tokyo, Japan

P-408 Progressive Base Excess Decline - A Prognostic Indicator of Early Mortality in Liver Transplant Recipients
Sang Kim, New York, United States

P-409 Chinese Citizen Voluntary Donors with Infections in Liver Transplantation: Could they Transmit Infections to the Recipients?
C.J Cai, Guangzhou, China

P-410 Anesthetic Management of a Low Weight Child Receiving Living Liver Transplantation
Fisun Bulutcu, Istanbul, Turkey

P-411 Postoperative Pain is Associated with Prolonged Hospital Stay in Liver Transplantation
Ahmed Addelhafez, Assiut, Egypt

P-413 Blood Glucose Levels and the Blood Transfusion in Adult Living Donor Liver Transplantation
Chia-Jung Huang, Kaohsiung, Taiwan, Republic of China

P-414 Plasma Free Concept for OLTx in IKEM Prague
Pavel Vychodil, Prague, Czech Republic

P-415 Incidence of Post Reperfusion Syndrome in Patients Submitted to Liver Transplantation
Derli C Munhoz, Campinas, Brazil

P-416 Application of Mechanical Ventilation in the Prone Position Combined with Pyloric Feeding in Liver Transplant Patients with Moderate to Severe ARDS
Z.X Tang, Guangzhou, China
Scientific Programme

P-417  Hyperfibrinolysis in Liver Transplant as a Cause of Bleeding Both in the Beginning and 10 Hours after Surgery: A Case Report
Bruno Vilanova, Rio de Janeiro, Brazil

P-418  Anesthesia Method in LT in our Clinic
Hakan Kilercik, Istanbul, Turkey

P-419  Cardiac Temponade 90 Days after LDLT and Unilateral Adrenalectomy
Parshotam Lal Gautam, Ludhiana, India

P-420  Liver Autotransplantation for a Retroperitoneal Tumor with IVC Involvement
Cosmin Guta, Weston, United States

P-421  Liver Transplantation in a Patient with Severe and Chronic Hyponatremia
Atish Pal, New Delhi, India

P-422  Surprise: Unexpected Difficult Intubation in Both Living Donors and Recipient and Successful C-MAC Videolaryngoscope Experience
Fisun Bulutcu, Istanbul, Turkey

Poster Sessions
11:30 - 12:00

Poster Session 3: Basic Sciences

P-423  itga3 Promotes Proliferation and Cell Cycle Progress in Intrahepatic Cholangiocarcinoma
Yu Huang, Hangzhou, China

P-424  Liver Regeneration and Function Recovery after Liver Resection in Rats Receiving Omega-3 Fatty Acids
Moo-Hyun Kim, Wonju, Korea, Republic of

P-425  Isoflurane Preconditioning Alleviated Murine Liver Ischemia and Reperfusion Injury by Restoring AMPK/mTOR-mediated Autophagy
Zhuqing Rao, Nanjing, China

P-426  GB83, a Novel Protease-activated Receptor 2 Antagonist, Inhibit Hepatocellular Carcinoma Progression through Autophagy, Proliferation and Migration
Chih-Che Lin, Kaohsing, Taiwan, Republic of China

P-427  Low Expression of the Mfn2-related Gene NAV3 is Associated with Poor Survival in Hepatocellular Carcinoma
Xiaohu Zhou, Hangzhou, China

Alessandra Bertacco, New Haven, United States

P-429  Study of Hepatocyte Proliferation Regulated by miR26a Activating Mdm2 Pathway
Jian Zhou, Guangzhou, China

P-430  Semaphorin3C is Downregulated in Hepatocellular Carcinoma and its Efficacy in the Prognosis of HCC
Panyisha Wu, Hangzhou, China
Scientific Programme

P-432 Augmentation of Liver Regeneration in Porcine Extended Liver Resection with Hepatocyte Transplant in Spleen
Ken Min Chin, Singapore, Singapore

P-433 Novel Concept of Induced Secretome which Maximizes the Potential of Stem Cells in the Mice with Hepatic Failure
Say-June Kim, Daejeon, Korea, Republic of

P-435 Red Blood Cell Distribution Is Positively Correlated with Neutrophil-to-Lymphocyte Ratio in Association with Low CD34 and GATA2 Levels after Living Donor Liver Transplantation
Kuang-Den Chen, Kaohsiung, Taiwan, Republic of China

P-436 Combined Liver-kidney Perfusion Enhances Protective Effects of Normothermic Perfusion on Livers Grafts from Donation after Cardiac Death
Zhiyong Guo, Guangzhou, China

P-437 Cytotoxicity of FK506 through TRAIL, Fas and TLR4 Signaling Pathway in Human Jurkat T Cells
Choi Soo Jin Na, Gwangju, Korea, Republic of

P-438 The Research of Molecular Mechanism of PDE7A in Hepatocellular Carcinoma
Minjie Xie, Hangzhou, China

P-439 The Effect of a Novel Antioxidant DHL-HisZn on Hepatic Stellate Cell Activation
Li-Wen Hsu, Kaohsiung, Taiwan, Republic of China

P-440 Pigment Epithelium-derived Factor Participates in the Inhibitory Effects of 1,25-dihydroxyvitamin D3 on Adipogenic Differentiation
Kuang-Tzu Huang, Kaohsiung, Taiwan, Republic of China

P-441 Histone Methyltransferase EZH2 Was Involved in the Mechanism of let-7e Inhibition of TNF-α Expression
Junqi Huang, Guangzhou, China

P-442 Evaluation of Blood Thiamine and Pyridoxine Levels in Patients with Chronic Liver Disease: A Prospective Study
Sami Akbulut, Malatya, Turkey

Poster Sessions
11:30 - 12:00

Poster Session 3: Extended Criteria Donor / Disease Transmission

P-443 Dual Aortic-portal Perfusion of Octogenarian Grafts Prevents Post-liver Transplant Ischemic-type Biliary Lesions
Davide Ghinolfi, Pisa, Italy

P-444 Successful Liver and Renal Transplantation from a Donor Suffering from Cryptococcus meningitis
Laura Ioana Mazilescu, Essen, Germany

P-445 Livers from Brain Dead Donors with Alcohol Abuse for Liver Transplantation
Giorgio Rossi, Milano, Italy

P-446 Is Surgeon’s Decision Enough to Define a Steototic Liver Graft?
Ercan Korkut, Erzurum, Turkey
Scientific Programme

P-447  Comparison of Outcomes between Expanded Criteria and Standard Criteria Donors after Liver Transplantation: A Single-centre Experience
Luca Toti, Rome, Italy

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Hepatitis B/C

P-448  Safety and Efficacy of Interferon-free Antiviral Therapy in Patients with Recurrent Hepatitis C after Liver Transplantation
Ilka Boin, Campinas, Brazil

P-449  Management of Hepatitis C Virus with Direct Acting Antivirals in Liver Transplantation Setting: A Korean Single-center Experience
Dongkyu Oh, Seoul, Korea, Republic of

P-450  Resolution of Diabetes Mellitus with Sofosbuvir and Ribavirin Treatment after Liver Transplantation for Chronic Hepatitis C
Yang Won Nah, Ulsan, Korea, Republic of

P-451  Successful Treatment of Fibrosing Cholestatic Hepatitis with Daclatasvir and Asunaprevir after Liver Transplantation
Jeong-Ik Park, Busan, Korea, Republic of

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Immunosuppression

P-452  Does Early Tacrolimus Exposure Affect Long-term Outcome in Patients Treated de Novo with Once-daily Tacrolimus after Liver Transplantation?
Mikel Gastaca, Bilbao, Spain

P-453  Immune Checkpoint Inhibitor Induced Severe Cholestasis and Loss of Bile Ducts in a Liver Transplant Patient
Marius Braun, Petah Tikva, Israel

P-454  Incidence of de Novo Tumors after Liver Transplantation and Influence on Survival of Conversion to m-TOR Inhibitors
Mónica Serrano Navidad, L'Hospitalet de Llobregat, Spain

P-455  Use of Everolimus in Liver Transplantation: An Australian Experience
Ken Liu, Sydney, Australia

P-456  Complete Response to Immunosuppression in Biopsy-proven Chronic Cellular Rejection in Liver Transplantation. A Report of Two Cases
María Sierra Morales, Madrid, Spain

P-457  HHV-6 Infections and Clinical Implications in Liver Transplant Recipients, Report of Four Cases
Javier Graus Morales, Madrid, Spain
Scientific Programme

P-458  The Experience of mTOR Inhibitors Combined with Tacromlimus in Living Donor Liver Transplantation
Sheng-Chih Kuo, Kaohsiung, Taiwan, Republic of China

P-459  Successful Treatment of Tacrolimus Induced Hemolytic-uremic Syndrome after LDLT
Nurhak Aksungur, Erzurum, Turkey

P-460  Hepatic Vein Thrombosis after Administration of Anti-thymocyte Globulin to Treat Acute Cellular Rejection Following Living-donor Liver Transplantation: A Case Report
Wataru Nakanishi, Sendai, Japan

Poster Session 3: Living Donor

P-461  Right Lobe Living Donor Liver Transplantation - Does the Middle hepatic Vein (MHV) Controversy Affect the Outcomes of Donors and Recipients?
Chun Han Nigel Tan, Singapore, Singapore

P-462  Laparoscopic Approach for Living Donor to Paediatric Liver Transplant. A Single Centre Experience of the First 5 Cases in Spain
Javier Briceño, Cordoba, Spain

P-463  Predicting Factors Impact to Survival after Recurrence in Living Donor Liver Transplantation in Patients with Hepatocellular Carcinoma - Single Center Experience
Chih-Chi Wang, Kaohsiung, Taiwan, Republic of China

P-464  Expanding Donor Pool - Living Liver Donor with Absent IVC
Rajesh Dey, New Delhi, India

P-465  The Challenge, Problem and Outcome in Developing Pediatric Living Donor Liver Transplantation Program in a Single Referral Hospital in Indonesia
Tri Hening Rahayatri, Jakarta, Indonesia

P-466  Donor Safety in Living Donor Liver Transplantation at a Low Volume Center
Aravind Kidambi Seshadri, Bangalore, India

P-467  Living Donor Liver Transplantation in Budd Chiari Syndrome: Surgical Challenges and Outcomes
Manoj Kumar Ayyappath, Noida, India

P-468  Donor and Recipient CMV Status in East; Are Infants at Higher Risk for CMV Infection Post Liver Transplant; Does Preemptive Gancyclovir Therapy Helps?
Neelam Mohan, Gurgaon, India

P-469  Safety of Living Donors in 144 Consecutive Living Donor Liver Transplants
Vibha Varma, Mumbai, India

P-470  Cmv Infection after Live Donor Liver Transplantation
Mohamed El-Saadany, Mansoura, Egypt

P-471  Swing Living Donor Liver Transplantation: Three Case Reports
Murat Akyıldız, Istanbul, Turkey
Scientific Programme

P-472  **Emerging Egyptian Living Donor Liver Transplantation Program: Preliminary Analysis**  
Amr El Fouly, Cairo, Egypt

P-473  **Change in Quality of Life of Donors after Living Donor Liver Transplantation**  
Elvan Onur Kırımker, Ankara, Turkey

P-474  **Gene Expression Profiling Analysis in Rat Small-for-Size Liver Transplantation**  
Haiyang Xie, Hangzhou, China

P-475  **The Influenced of Middle Hepatic Vein Reconstruction in Adult Right-lobe Living Donor Liver Transplantation**  
Haijun Guo, Hangzhou, China

P-476  **Early Experience of Adult Living Donor Liver Transplantation from Thailand**  
Sunhawit Junrungsee, Chiang Mai, Thailand

P-477  **Old Live Donor Candidate with Diffuse Hamartoma and Cysts in Both Lobes of the Liver (Case)**  
Geun Hong, Seoul, Korea, Republic of

P-478  **One Way HLA Mismatch between Donor and Recipient is a Risk Factor for GVHD in Live Donor Liver Transplant - A Case Series**  
Deepak George, New Delhi, India

P-479  **Living Liver Donor with Fasciola Hepatica: First Case in the Liver Transplantation Society**  
Sami Akbulut, Malatya, Turkey

P-480  **Control-matched Study of the Postoperative Evolution after Right Hepatectomy Performed for Living Liver Donation vs. for Liver Disease**  
Mihai-Calin Pavel, Barcelona, Spain

P-481  **Outcome of Donor Hepatectomy: Single-center Experience**  
Hakan Sozen, Ankara, Turkey

P-482  **Massive Subcutaneous Emphysema, Pneumoperitoneum, Pneumoretroperitoneum, and Pneumoscrotum Following ERCP in Living Liver Donor: Apparent Life-threatening Event**  
Sami Akbulut, Malatya, Turkey

P-483  **The First Case of Pure 3D Laparoscopic Living Donor Hepatectomy in Kazakhstan**  
Kaliev Aset, Aktobe, Kazakhstan

P-484  **Living Donor Liver Transplantation in Jehovah’s Witnesses Patients, Donor and Receptor**  
Camila Girão, Rio de Janeiro, Brazil

P-485  **Liver Volume Calculation for Living Donor Liver Transplantation with the Surgeon´s Point of View**  
Adil Baskiran, Malatya, Turkey

P-486  **Unusual Case of MDR3 Deficiency in a Transplanted Living Related Liver Transplantation**  
Walid Faraj, Beirut, Lebanon

P-487  **Our 2 Years of Experience in Living Donor Liver Transplantation**  
Kakhaber Kashibadze, Batumi, Georgia

P-488  **A Rare Unsuspected Condition to Abandon Liver Donor Operation, Peliosis Hepatis: A Case Report**  
Fahrettin Yildiz, Gaziantep, Turkey
Scientific Programme

P-489 Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma Using “No-touch” Technique: First Case in Myanmar
Tin Tin Mar, Yangon, Myanmar

Poster Session 3: Malignancies

P-490 The Function of TNFSF4 in the Development of Hepatocellular Carcinoma and the Treatment of Sorafenib
Jin Pingbo, Hangzhou, China

P-491 Liver Transplantation for Hepatocellular Carcinoma (HCC)
Rasim Farajov, Izmir, Turkey

P-492 Seconder Primary Malignencies in Patients with Hepatocellular Carcinoma after Liver Transplantation: Single Center Experiences
Volkan Ince, Malatya, Turkey

P-493 Living Donor Liver Transplantation for Unresectable Mixed Hepatocellular and Cholangiocarcinoma: A Retrospective Analysis
Ashok Thorat, Taichung, Taiwan, Republic of China

P-494 A Heavy Metal Knocking at the Door - Transarterial Radioembolization with Rhenium-188 as a Bridging Strategy for Treating Hepato Cellular Carcinoma Prior to Liver Transplant
Rajeev Sinha, Coimbatore, India

P-496 Multiple Steps Selection Criteria in Living Donor Liver Transplantation for Hepatocellular Carcinoma Achieves Better Outcomes
Chih-Che Lin, Kaohsing, Taiwan, Republic of China

P-497 A Preoperative Score for Predicting Survival among Patients with Resectable Pancreatic Adenocarcinoma
Bingjie Ju, Hangzhou, China

P-498 The Ubiquitin Ligase TRIM25 Positively Promotes the Tumor Cell Progression in Intrahepatic Cholangiocarcinoma
Zhengze Xue, Hangzhou, China

P-499 Favorable Long-term Prognosis of Hepatitis B Surface Antigen Positive Intrahepatic Cholangiocarcinoma for Both Hepatic Resection and Incidental Liver Transplantation via Inhibiting Cancer-associated Lymphangiogenesis
Jinyang Gu, Shanghai, China

P-500 Experience on Therapy for Perihilar Cholangiocarcinoma via Neoadjuvant Chemoradiotherapy Combined with Liver Transplantation
Xiao-Lei Shi, Nanjing, China

P-501 Living Donor Liver Transplantation for Unresectable Metastatic Gastrointestinal Stromal Tumor (GIST) of the Liver
Ercan Korkut, Erzurum, Turkey

P-502 Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma
Vassil Mihaylov, Sofia, Bulgaria
Scientific Programme

P-503 Hepatocellular Carcinoma with Spindle Cell Component Underwent Living Donor Liver Transplantation: A Case Report
TAE BEOM Lee, Yansan-si, Korea, Republic of

P-504 Relapsed Metastatic Pheochromocytoma Treated with Liver Transplantation
Hengkai Zhu, Hangzhou, China

P-505 Can Hepatectomy Be a Down-stage Procedure for Advance HCCs Patient before Liver Transplantation?
Kaman Kuok, Changhua, Taiwan, Republic of China

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Outcomes

P-506 ECMO in Liver Transplant
Naeem Goussous, Baltimore, United States

P-507 Preliminary Result of ABO Incompatible Liver Transplant Using Immunoadsorption
Nishant Shiv, New Delhi, India

P-508 Arterial and Biliary Complication Free Survival (ABC FS) a New Method to Evaluate Results of Liver Transplantation. Example on Liver Preservation Solution
Eric Savier, Paris, France

P-509 Association of Feelings, Impact on the Family and Social Support of Patients Candidates to Transplant of Liver
Ilka Boin, Campinas, Brazil

P-510 Surgical Outcome of Liver Transplantation: Gazi University/Ankara-Turkey Experience
Hakan Sozen, Ankara, Turkey

P-511 Positive Anti-mitochondrial Antibody Has Little Impact on Long-term Survival of Primary Biliary Cirrhosis Patients after Liver Transplantation
Jun Ding, Hangzhou, China

P-512 Anticoagulation Protocols Following Liver Transplant
Alexa Strachan, London, United Kingdom

P-513 Chronic Renal Dysfunction after Living-donor Liver Transplantation Using Calcineurin-based Immunotherapy with Basiliximab Induction
Chikashi Nakanishi, Sendai, Japan

P-514 The Feasibility of Thrombectomy for Portal Vein Thrombosis during Liver transplantation
Seung Hwan Song, Seoul, Korea, Republic of

P-515 Acute Kidney Injury in Cirrhotic Patients is a Dramatic Predictor of Mortality and Length of Stay in Both Referral and Community Hospitals
David Victor, Houston, United States

P-516 Liver Transplantation in Kazakhstan: Current Status and Outcomes
Zhassulan Baimakhanov, Almaty, Kazakhstan

P-517 Impact of Recipient with Hypertension on the Survival after Liver Transplantation
Jie Xiang, Hangzhou, China
P-518  Early Anticoagulation with Heparin and Maintenance Antiaggregation with Aspirin Does Not Reduce Risk of Hepatic Artery Thrombosis among Liver Transplant Recipients with Familial Amyloid Neuropathy
Thalita Amaral Amaro Adami, São Paulo, Brazil

P-519  Restoration of a Liver Transplant Center
Martin Hertl, Chicago, United States

P-520  Outcomes of Left Lobe Graft in Adult to Adult Living Donor Liver Transplantation without Inflow Modulation - A Single Centre Experience
Biswajit Deuri, Delhi, India

P-521  The Clinico-pathological Behavior and Survival Outcome of Alphafeto Protein-negative Hepatocellular Carcinoma after Liver Transplantation: A Significant Category with Unclear Prognostic Criteria
Chee Chien Yong, Kaohsiung, Taiwan, Republic of China

P-522  Health Related Quality of Life in Living Donor Liver Transplant Recipients: An Indian Perspective
Ankush Golhar, New Delhi, India

P-523  Acute Kidney Injury after Liver Transplantation Does Not Affect Patient’s Mortality
Eun Ae Byun, ULSAN, Korea, Republic of

P-524  Outcome and Surgical Strategies in Patients with PVT Receiving Liver Transplantation
Dagmar Kollmann, Vienna, Austria

P-525  Role of Fibroscan for Surveillance of Asymptomatic NAFLD Patients
Jayshri Shah, Mumbai, India

P-526  Nursing Care of Patients with Mental Disorder after Early Upper Abdominal Multiple Organ Transplantation from Donor after Cardiac Death
Qiujiang Dou, Guangzhou, China

P-527  Hepatic Artery Stenosis, Incidence, Presentation and Treatment
Christopher Ibarra, New Haven, United States

P-529  Excellent Outcome after Living Donor Liver Transplantation for Wilson’s Disease: A Single Centre Experience
Neeraj Saraf, Gurgaon, India

P-530  Hepatopulmonary Syndrome and Liver Transplantation: Outcomes in Peru
Jose Chaman, Lima, Peru

P-531  Massive Mycotic Thrombosis Caused by Aspergillus fumigatus after Liver Transplantation
Jan-Paul Gundlach, Kiel, Germany

P-532  Incidence and Risk Factors for Herpes zoster after Liver Transplantation
Wontae Kim, Seoul, Korea, Republic of

P-533  Family Care Network for Organ Donors for Transplantation
Boin Ilka de Fátima Santana Ferreira, Campinas, Brazil

P-534  Liver Transplantation Results in our Center Newly Established
Zafer Sabuncuoğlu, Isparta, Turkey
Scientific Programme

P-535 Prospetive Follow up of Patients with Chronic Liver Disease Referred for a Liver Transplant: A Single Centre Study
Ankur Shah, Mumbai, India

P-536 Incidence and Treatment of Bile Stones after Liver Transplant
Mehmet Haberal, Ankara, Turkey

P-537 Initial Outcome of the First 20 Cases of Liver Transplantation in a Small Volume Center
Ho Joong Choi, Seoul, Korea, Republic of

P-538 Donor Age Impact on Graft and Recipient Survival Rate of Liver Transplantation: 20 Years of Experience (Spain)
Rebeca Hernandez Vaquero, Santiago de Compostela, Spain

P-539 Single Experience of Liver Transplantation Using Liver Donated after the Citizen’s Death in China
Chen Huanwei, Foshan, China

P-540 Intracranial Hemorrhage after Liver Transplantation: A Case
Seong-Hwan Chang, Seoul, Korea, Republic of

P-541 Portopulmonary Hypertension after Liver Transplantation: A Case report
Sung Pil Yun, Busan, Korea, Republic of

P-542 Early Experience for Setting Liver Transplantation Program at Beginning Center
Hyung Hwan Moon, Busan, Korea, Republic of

P-543 Very Late Hepatic Artery Thrombosis after Orthotopic Liver Transplantation: Report of Two Cases
Ana Garcia Garcia de Paredes, Madrid, Spain

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Patient Selection / Organ Allocation / Organ Recovery

P-544 The Effect of 12 Hours of Normothermic Machine Perfusion (NMP) on Type 2 DCD Grafts Discarded for Liver Transplantation
Mihai-Calin Pavel, Barcelona, Spain

P-545 Outcome of Patients Receiving Liver Transplantation at the Age of >65 Years
Dagmar Kollmann, Vienna, Austria

P-546 Liver Transplantation Using Pediatric versus Adult Donor Grafts in Adult Recipients
Zhiyong Guo, Guangzhou, China

P-547 The Impact of Time from Aortic Cross Clamp to Liver Extraction on Early Allograft Dysfunction
Dieter Adelmann, San Francisco, United States

P-548 Outcome of the Use of Pediatric Donor Livers in Adult Recipients: A Single Chinese Center Experience
Li Cheukfai, Guangzhou, China
Scientific Programme

P-549  Pre- and Post-operative Echocardiographic Differences between Simultaneous Liver-kidney (SLK) and Orthotopic Liver Transplant (OLT) Recipients
Aliaksei Pustavoitau, Baltimore, United States

P-550  Progress in the Treatment of Primary Hepatic Neuroendocrine Tumors and the Application of Liver Transplantation
Wenhao Ge, Hangzhou, China

P-551  The Performance of Four Tools in Prediction of Potential for Organ Donation after Cardiac Death in Neurocritical Patients: A Prospective, Multicenter, Observational Study
Zhiyong Guo, Guangzhou, China

P-552  A Rare Case of Hepatic Arteries Disappearance and Reappearance in ABO-incompatible Liver Transplantation
Zhang Wu, Hangzhou, China

P-553  A Case of a Successful Child-to-Adult Deceased Donor Liver Transplantation
Tae Wan Lim, Seoul, Korea, Republic of

P-554  Left Lobes with Less Fatty Components Seem to Be the Considerable Grafts for Living Donor Liver Transplantation
Fan Hsiu-Lung, Taipei, Taiwan, Republic of China

P-555  Risk Factors of Primary Graft Dysfunction after Liver Transplantation from DCD Donor
Jian Zhou, Guangzhou, China

P-556  Risk Factors of Biliary Complications after Liver Transplantation from Adult DCD Donor
Jian Zhou, Guangzhou, China

Poster Session 3: Pediatrics

P-557  Liver Transplantation in Pediatric Cystic Fibrosis Patients
Ilya Zhilkin, Moscow, Russian Federation

P-558  Successful Transplantation in an Infant with Complete Portal Vein Thrombosis
S Nikhil, Delhi, India

P-559  Liver Transplantation in Glycogen Storage Disease Type I: A Single-Center Experience
Liping Cao, Hangzhou, China

P-560  Living Donor Liver Transplantation in a Baby with Wolman Disease: A Case Report
Yordanka Uzunova, Sofia, Bulgaria

Poster Session 3: Radiology / Interventional Radiology
Scientific Programme

P-561  Feasibility of UltraFast Doppler in Postoperative Evaluation of Hepatic Artery in Recipients Following Liver Transplantation
Heon-Ju Kwon, Seoul, Korea, Republic of

P-562  Management of Hepatic Encephalopathy(HE) in Adult Deceased Donor Liver Transplant(DDLT) Recipient with Persistent Portosystemic Shunts (PSS) in the Setting of Portal Vein (PV) Stenosis via Portal Venoplasty
Bethany Fast, Minneapolis, United States

P-563  Percutaneous Interventional Treatment of Severe Portal Vein Stenosis and Thrombosis after Living-donor Liver Transplantation.
Yang-Seok Koh, Jeonnam, Korea, Republic of

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Recurrent Disease / Pathology

P-564  The Impact of Histopathological Features of Primary Tumor to the Long-term Outcome of Liver Transplants for Hepatocellular Carcinoma: A 10-year Follow-up
Mehmet Haberal, Ankara, Turkey

P-565  The Results of Morphological Examination of Liver in Posttransplant Period
Bibigul Ilyassova, Almaty, Kazakhstan

P-566  Successful Liver Transplantation in Drenanicotic Anemia
Carlos Florez Zorrilla, Ciudad de Mexico, Mexico

Poster Sessions
11:30 - 12:00
Poster Area

Poster Session 3: Surgical Techniques / Complications

P-567  Cavo-portal Hemitransposition in Liver Transplant with Complete Portal Vein Thrombosis
Federico Mocchegiani, Ancona, Italy

P-568  Liver Transplantation for Alcoholic Liver Disease: The Influence of Peri-operative Psychiatric Complication on Prognosis
Mangli Zhang, Hangzhou, China

P-569  Biliary Complications after Liver Transplantation From Donation after Citizen´s Death: A Single-center Experience in China
Dong Chen, Wuhan, China

P-570  A Case Report of Liver Transplantation Using a Graft from a Donor with Situs Inversus Totalis
Jinzhen Cai, Tianjin, China

P-571  Middle Hepatic Vein Thrombosis Caused by Biloma at Liver Resection Margin after Living Donor Liver Transplantation Using Modified Right Lobe Graft
Hyung Woo Park, Ulsan, Korea, Republic of
Scientific Programme

P-572 Treatment Strategy for Hepatocellular Adenoma and Liver Adenomatosis: The Role of Extended Hepatectomy and Living Donor Liver Transplantation as a Backup Procedure
Rodrigo Vincenzi, Sao Paulo, Brazil

P-573 Salvage Sandwich Method for Portal Vein Reconstruction with Recipient’s Coronary Vein
Ting Lung Lin, Kaohsiung, Taiwan, Republic of China

P-574 Acute Cellular Rejection after Liver Transplantation from Donation after Cardiac Death in Mainland China: Outcomes from the CLTR Database
Zenglei He, Hangzhou, China

P-576 A Case of Early Organizing Portal Vein Thrombosis Followed by Arterio-portal Shunt without Hepatic Dysfunction after Liver Transplantation
Koo Jeong Kang, Daegu, Korea, Republic of

P-577 Hepatic Venous Reconstruction on a Previously Stented Inferior Vena Cava (IVC): Report of a Case with Budd – Chiari Syndrome (BCS)
Can Karaca, Izmir, Turkey

P-578 Severe Complications of Percutaneous Transhepatic Biliary Drainage for Biliary Complications after Failed Endoscopic Therapy in Liver Transplantation
Wen-Tsan Chang, Kaohsiung, Taiwan, Republic of China

P-579 Modified Portocaval Hemitransposition to Avoid Portal Hypertension in Liver Transplant
Arif Ali Khan, New Delhi, India

P-580 A Case of Pre-existing Aspergillus Brain Abscess Diagnosed and Treated after Liver Transplantation
Young Chul Yoon, Incheon, Korea, Republic of

P-581 Outflow Reconstruction in Domino Liver Transplantation
Vivekanandan Shanmugam, Coimbatore, India

P-584 Simultaneous Liver Pancreas-duodenum and Kidney Transplantation in a Patient with Hepatitis B Cirrhosis Combined with Chronic Renal Failure and Insulin Dependent Diabetes Mellitus
Jiang Li, Tianjin, China

P-585 Transverse Incisional Donor Right Hepatectomy: First Case in Myanmar
Pyae Pa Pa Kyaw, Yangon, Myanmar

P-586 Successful Management of Fournier Gangrene Fasciitis Following Liver Transplantation
Nicole Hornfeld, Graz, Austria

P-587 Anastomosis of Portal Vein and Bile Duct Anomaly in Living Donor Liver Transplantation
Kwangisk Chun, Daegu, Korea, Republic of

P-589 Portal vein Reconstruction through a Paracholedocal Vein in cavernous Transformation of Recipient Portal Vein: A Case Report
Ju Ik Moon, Daejeon, Korea, Republic of

P-590 A Case of Deceased Donor Liver Transplantation Using Renoportal Anastomosis in Patients with Diffuse Portomesenteric Thrombosis
Hyoung Tae Kim, Daegu, Korea, Republic of

P-591 A Case of One Orifice Outflow Reconstruction with Commercialized Dacron Y-graft in Right Liver Graft
Doo Jin Kim, Seoul, Korea, Republic of
Scientific Programme

P-592 Report of Two Cases of Acute Pancreatitis after Liver Transplantation for HCC
Qinfen Xie, Hangzhou, China

P-593 How to Manage Hilar Bile Duct Stenosis Caused by Hepatic Artery Insufficiency in Hilum after Cadaveric Donor Liver Transplantation
Samyoul Yoon, Anyang, Korea, Republic of

P-594 1 Case the Nursing of Children Organ Donations after Cardiac Death Donation of Liver in Adults with Portal Venous Thrombosis after Liver Transplantation
Huilin Chen, Guangzhou, China

P-595 Lessons Learned from Salvage Liver Transplantation for Post-hepatectomy Liver Failure: A Case Report
Hyung Hwan Moon, Busan, Korea, Republic of

P-596 Living-donor Liver Transplantation (LDLT) for Budd-Chiari Syndrome (BCS) with Resection and Reconstruction of Retrohepatic Vena Cava with Dacron Vascular Graft: A Case Report
Ayhan Dinckan, Istanbul, Turkey

Poster Sessions
11:30 - 12:00

Poster Session 3: Late breaking posters

LB P-25 Predicting Mortality in Transplant Recipients with Hepatocellular Carcinoma
Daniel James Firl, Cleveland, United States

LB P-27 Massive Teratoma and Liver Resection in A Young Jehovah’s Witness
Victoria McMullan, Dublin, Ireland

LB P-28 Effect of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence in Liver Transplant Patients: Malatya Experience
Ersan VeySEL, Malatya, Turkey

LB P-29 Milan and UCSF Criteria for Liver Transplantation to Treat Hepatocellular Carcinoma
Tufan Egeli, Izmir, Turkey

LB P-30 Implantation Time During Liver Transplantation Impairs Outcome
Ina Jochmans, Leuven, Belgium

LB P-31 Establishment of Predictive Model for Microvascular Invasion of Hepatocellular Carcinoma and Clinical Usage of the Model for Decision of Surgical Strategy
Hidetoshi Nitta, Villejuif, France

LB P-32 Complete Blood Count of Deceased Donors and The Results of Liver Transplantation
Jaroslaw Czerwiński, Warsaw, Poland

LB P-33 Patient Perspectives of Teamwork on a Transplant Surgery Team
Yoogoo Kang, Philadelphia, United States

LB P-34 Impact of Sarcopenia on Outcome in Living Donor Liver Transplantation
Vaibhaw Kumar, Delhi, India

LB P-35 Incidence and Outcome of CMV Infection in Patients with Liver Transplantation
María Rodriguez-Soler, Alicante, Spain
Scientific Programme

LB P-36  Procoagulant Imbalance in Liver Transplant Candidates and Its Implication for the Early Allograft Dysfunction after Living-Donor Liver Transplantation
Hye-Won Jeong, Seoul, Korea, Republic of

LB P-37  Extraction Time During Retrieval Impairs Liver Transplant Outcome
Ina Jochmans, Leuven, Belgium

LB P-38  D-Meld Score As a Predictor of Post Donation-After-Cardiac-Death Liver Transplant Prognosis in Acute on Chronic Liver Failure Recipients with HBV Infection
Mingchun Lai, Hangzhou, China

LB P-39  Split-Liver Program, The New Allocation System in Italy: The Results of First Year Activity
Silvia Trapani, Roma, Italy

LB P-41  Survey Results Following the Establishment of the Educational Program in Multi-Organ Procurement Including Liver Recovery with E-learning and Simulation Using Large Animals
Hiroyuki Furukawa, Asahikawa, Japan

LB P-42  First Case Report of Successful Combined Open Heart Surgery and Living Donor Liver Transplantation for Child with Alagille syndrome
Sasidhar Reddy, Hyderabad, India

LB P-44  Combined Arterial Embolization, Portal Vein Ligation and Hepatectomy for Giant Liver Adenoma
Angel Pierini, Santa Fe, Argentina

LB P-45  Liver Transplantation with Renoporal Bypass for Extensive Portomesenteric Venous Thrombosis: Case Report
Tomaz J. M. Grezzana-Filho, Porto Alegre, Brazil

LB P-46  Surgical Revascularization As an Effective Treatment for Early Arterial Thrombosis Following Liver Transplantation
Marcio F. Chedid, Porto Alegre, Brazil

LB P-47  Biliary Complications After Liver Transplantation
Serdar Arslan, Istanbul, Turkey

Sasidhar Reddy, Hyderabad, India

LB P-49  Biliary Strictures after Living Donor Liver Transplantation - Single Center Experience
Maxat Doskhanov, Almaty, Kazakhstan

LB P-50  Low Donor Serum Albumin Level Predicts Ischemic-Type Biliary Lesions after Donation after Cardiac Death Liver Transplantation
Weiliang Xia, Hangzhou, China

LB P-51  Modified Posterol Cavoplasty for Outflow Reconstruction of the Right Liver Graft with Middle Hepatic Vein or its Tributaries in Living Donor Liver Transplantation
Yi-Ying Lee, Taipei, Taiwan, Republic of China

LB P-52  Ante Situm Hepatic Veins and IVC Reconstruction with in Situ Cold Perfusion of Liver for Chronic Budd-Chiari Syndrome
Madhusudhan Chinthakindi, Hyderabad, India

LB P-53  Endoscopic Treatment of Biliary Complications after Liver Transplantation
Birol Baysal, Istanbul, Turkey
Scientific Programme

LB P-54 Laparoscopic Incisional Hernia Repair Post-Liver Transplantation: A Single Center Experience
Gabriel Pompermayer, Clichy, France

Poster Sessions
11:30 - 12:00

Surgical Video Presentations Session 3

eP-8 Laparoscopic Release of Median Arcuate Ligament Post-liver Transplant
Martin Montenovo, Seattle, United States

eP-9 Totally Laparoscopic Living Donor Left Hepatectomy for Liver Transplantation in a Child
Seok-Hwan Kim, Seoul, Korea, Republic of

eP-10 Large Collateral Vein for Portal Inflow in Liver Transplantation with Portal Vein Thrombosis
Xiangcheng Li, Nanjing, China

Featured Symposium
12:00 - 13:30

Long term outcomes

Chairs:
Laura Rubbia Brandt, Genève, Switzerland
John O’Grady, London, United Kingdom

Current challenges of long term outcome of liver transplant recipients 12:00
Michael R. Charlton, Chicago, United States

Biomarkers of tolerance and immunosuppression withdrawal 12:20
Alberto Sanchez Fueyo, London, United Kingdom

Histopatology of the transplanted liver-what we can learn from protocol biopsies 12:40
Eva Sticová, Prague, Czech Republic

Antibody-mediated rejection in LT 13:00
Timucin Taner, Rochester, United States

Featured Symposium
12:00 - 13:30

Live donor liver transplantation

Chairs:
Giuliano Testa, Dallas, United States
Mark Ghobrial, Houston, United States

Pediatric and adult live donor LT 12:00
Roberto Troisi, Gent, Belgium
Scientific Programme

**Surgical tips for a successful LT procedure**  
Deok-Bog Moon, Seoul, Korea, Republic of

**Minimvasive live donor liver surgery**  
Ki-Hun Kim, Seoul, Korea, Republic of

**Risks of live donor liver donation - revisited**  
Elizabeth Pomfret, Denver, United States

Featured Symposium  
12:00 - 13:30  
Meeting Hall 4

**Fulminant liver failure**

**Chairs:**  
Gianni Biancofiore, Pisa, Italy  
Alistair Lee, Edinburgh, United Kingdom

**Managing the brain**  
William Bernal, London, United Kingdom

**ICU support: beyond the brain**  
Catherine Paugam-Burtz, Paris, France

**Transplant options for FHF**  
Yaman Tokat, Istanbul, Turkey

**Intraoperative challenges**  
James Findlay, Rochester, United States

Featured Symposium  
12:00 - 13:30  
Meeting Hall 5

**Liver machine perfusion**

**Chairs:**  
Gabriel Oniscu, Edinburgh, United Kingdom  
Magdy Attia, Leeds, United Kingdom

**Liver machine perfusion techniques**  
Peter Friend, Oxford, United Kingdom

**Effect of machine perfusion on ischemic-type biliary lesions**  
Robert Porte, Groningen, Netherlands

**What sort of liver, when and to which patient?**  
Pierre-Alain Clavien, Zurich, Switzerland

**Markers of early allograft failure**  
Kim Olthoff, Philadelphia, United States
Scientific Programme

Sponsored Lunch Symposium
13:30 - 15:00
Forum Hall

Sponsored Lunch Symposium

For more details, please visit the 2017 Joint International Congress of ILTS, ELITA & LICAGE website.

Sponsored Lunch Symposium
13:30 - 15:00
Panorama Hall

Sponsored Workshop

For more details, please visit the 2017 Joint International Congress of ILTS, ELITA & LICAGE website.

Others
15:00 - 16:00
Panorama Hall

Women in Transplantation Networking Session

Lecture
15:00
Marina Berenguer, Valencia, Spain

Town Hall Discussion
15:20

Concurrent (LICAGE)
15:30 - 17:00
Congress Hall

Anesthesia/CCM Interactive Case Presentations

Chairs:
James Findlay, Rochester, United States
John Klinck, Cambridge, United Kingdom

LB 0-1
Pulmonary Hypertension Assessment in Patient with Arrhythmogenic Right Ventricle Prior to Liver Transplantation: A Case Report
15:30
Fatimah Alsalah, Dammam, Saudi Arabia

Management of severe hepatopulmonary syndrome
16:00
Geraldine Diaz, Chicago, United States

Management of primary non-function
16:30
Katharina Willuweit, Essen, Germany
Fuat Saner, Essen, Germany
Scientific Programme

Concurrent (ELITA)
15:30 - 17:00

You cannot live a long-term without a good short

Chairs:
Wojciech Polak, Rotterdam, Netherlands
Pavel Taimr, Prague, Czech Republic

O-93  Cell-free DNA and miRNAs Correlate with Degree of Graft Injury post Liver Transplantation
Debalina Bagchi, Charlottesville, United States
15:30

O-94  Impact of Early Allograft Dysfunction (EAD) and Its Components on Patient Survival Following Liver Transplantation (LT): Long-term Outcomes up to 10 Years
Burcin Ekser, Indianapolis, United States
15:40

O-95  The Golden Hour: Length of Combined Warm Ischemia Time Presages Development of Severe Acute Kidney Injury after DCD Liver Transplantation
Marit Kalisvaart, Birmingham, United Kingdom
15:50

O-96  Liver Transplant Outcomes from Declined Liver Allografts: How Much Worth the Risk of Transplanting Organ when Others Say “No”
Francesca Marcon, Birmingham, United Kingdom
16:00

O-97  Novel Benchmarking in a Large Multicentric Cohort of “Ideal” Liver Transplantation to Quantify Increased Risk of Re-transplantation of the Liver
Xavier Muller, Zurich, Switzerland
16:10

O-98  Lower Level of Care Adversely Impacts the Outcomes of Liver Transplantation
Paolo De Simone, Pisa, Italy
16:20

O-99  Adult Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure in High MELD Patients
Deok-Bog Moon, Seoul, Korea, Republic of
16:30

O-100  Recurrent HCC after Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation
Hala Muaddi, Toronto, Canada
16:40

O-101  Higher Risk of Preterm Birth for Women with Renal Impairment Post Liver Transplantation
Enoka Gonsalkorala, London, United Kingdom
16:50

Concurrent Oral Abstract Session
15:30 - 17:00

Patient Selection and Organ Recovery

Chairs:
John O’Grady, London, United Kingdom
Jaroslav Chiupac, Prague, Czech Republic
O-102  Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation  
Neil Mehta, San Francisco, United States  
15:30

O-103  Liver Transplantation for HCC Patients with High AFP Level - How to Select?  
WC Dai, Pokfulam, Hong Kong  
15:40

O-104  Outcome of Liver Transplant Recipients after the First Episode of Bacterial Infection  
Alberto Ferrarese, Padua, Italy  
15:50

O-105  The Objective Liver Frailty Index Significantly Improves the Clinician “Eyeball Test” to Predict Mortality in Liver Transplant Candidates  
Jennifer Lai, San Francisco, United States  
16:00

O-106  Association of Cardiac Structural Abnormalities to the Frail Phenotype in Liver Transplant Candidates: From the Functional Assessment in Liver Transplantation (FrAILT) Study  
Lorena Puchades, Valencia, Spain  
16:10

O-107  Normothermic Regional Perfusion Improves Outcomes after Liver Transplantation from cDCD Donors  
Gabriel Oniscu, Edinburgh, United Kingdom  
16:20

O-108  Human Liver Transplantation after Normothermic Machine Perfusion (NMP), the First Report in the United States  
Qiang Liu, Cleveland, United States  
16:30

O-109  The Impact of Hypothermic Oxygenated Perfusion on Liver Viability - Tested during Normothermic Machine Perfusion  
Yuri Boteon, Birmingham, United Kingdom  
16:40

O-110  Repair on the Pump: Effective Delivery of Mesenchymal Stromal Cells (MSCs) to Liver Grafts during Isolated Machine Perfusion  
Monique M.A. Verstegen, Rotterdam, Netherlands  
16:50

Concurrent Oral Abstract Session  
15:30 - 17:00  
Meeting Hall 4

Living Donor

O-111  Cytomegalovirus Latency Exacerbated Small-for-Size Liver Graft Injury Through Activation of CCL19/CCR7 in Hepatic Stellate Cells  
Hui Liu, Hong Kong, Hong Kong  
15:30

O-112  Living Donor Liver Transplant for Acute on Chronic Liver Failure: Single Centre Experience  
Sanjay Kumar Yadav, Gurgaon, India  
15:40
Scientific Programme

O-113 Worldwide Survey of Live Liver Donor Selection Policies: Results from 19,556 Living Donor Liver Transplants
Arvinder Singh Soin, Gurugram, India

O-114 The Socioeconomic Characteristics of Anonymous Living Liver Donors
Aloysious D Aravinthan, Toronto, Canada

O-115 The Ways to Perform Successful Living Donor Liver Transplantation Using Left Lobe Grafts in Adults
Toru Ikegami, Fukuoka, Japan

O-116 Post Operative Pain Management in Live Liver Donor Hepatectomy - Experience with 1506 Cases for a Single Centre
Nikunj Gupta, Gurgaon, India

O-117 Increased Proficiency in Both Left and Right Living Donor Hepatectomy Leads to Improved Donor Outcomes
Viola Huang, Kaohsiung, Taiwan, Republic of China

O-118 A Randomized Trial Comparing Combined Hepatic Artery and Portal Vein Flushing versus Portal Vein Flushing Alone in Live Donor Liver Transplantation
Johns Shaji Mathew, Kochi, India

O-119 De-novo Portal Vein Thrombosis after Adult-to-Adult Living Donor Liver Transplantation (LDLT) Does Not Impact on Long-term Outcome
Ivan Linares, Toronto, Canada

Concurrent Oral Abstract Session
15:30 - 17:00 Meeting Hall 5

Radiology

Chairs:
Kevin Kim, New Haven, United States
Marco Senzolo, Padua, Italy

O-120 BOLD Imaging in Quantification of Acute Cellular Rejection Post Liver Transplantation
Hsien Jen Chiang, Kaohsiung, Taiwan, Republic of China

O-122 Segmental Variation in Liver Density and its Implications for Liver Biopsy and Evaluation of Focal Liver Lesions
Bhagya Gunetilleke, Colombo, Sri Lanka

O-123 Accuracy of Computed Tomography for Detecting Hepatic Steatosis in Donors for Liver Transplantation: A Meta-analysis
Zhiyong Guo, Guangzhou, China

O-124 Chronic Portal Vein Thrombosis after Pediatric LDLT Treated by Transmesenteric Approach and Stent Placement: Medium Term Results
Rodrigo Vincenzi, Sao Paulo, Brazil

O-125 Intraoperative Portal Vein Stenting in LDLT
Lim Wei-Xiong, Kaohsiung, Taiwan, Republic of China
Scientific Programme

O-126 Prediction of Histologic Grade and Microvascular Invasion in Liver Transplantation Patient with HCC Using CT and MR
Je Ho Ryu, Yang-san, Korea, Republic of

O-127 Outcome of Children with PFIC after Living Donor Liver Transplantation
Esra Polat, Istanbul, Turkey

O-128 N-butyl-2 Cyanoacrylate Embolus in the Graft Portal Vein after Portosystemic Collateral Embolization in Recipients of Liver Transplantation: What is the Clinical Significance?
Kyoung Won Kim, Seoul, Korea, Republic of

O-121 Anticoagulation of Post-transplantation Portal Vein Stenting

Poster Sessions
17:00 - 17:30 Poster Area

Surgical Video Presentations Session 4
eP-12 Auto-transplantation of the Liver for Ex-vivo Resection of Intrahepatic Caval Leiomyosarcoma
Paolo Muiesan, Birmingham, United Kingdom

Concurrent Oral Abstract Session
17:30 - 19:00 Forum Hall

Recurrent disease/ Pathology

Chairs:
Faouzi Saliba, Villejuif, France
Marco Senzolo, Padua, Italy

O-129 Retrospective Study to Determine the Predictors of Development of Non-alcoholic Fatty Liver Disease (NAFLD) post Liver Transplantation
Zita Galvin, Toronto, Canada

O-130 Low Rate of Significant Fibrosis and Cirrhosis Using Transient Elastography after Liver Transplantation
James Fung, Hong Kong, Hong Kong

O-131 Histological Findings of Liver Allograft Biopsies in an Adult Population that Received a Transplant at a Pediatric Age
Maria Fernanda Veltens, Buenos Aires, Argentina

O-132 Pathological Signs of Graft Failure in Pediatric Patients after Liver Transplantation
Rie Irie, Tokyo, Japan

O-133 Hepatic Progenitor Cells and their Stem Cell Niche - An Immunopathologic Study of Liver Explants in Acute and Chronic Liver Failure of Varied Etiologies
Archana Rastogi, Delhi, India
### Scientific Programme

#### O-134
**Different Kinetics of Hepatocyte and Cholangiocyte Regeneration by Recipient Epithelial (Stem) Cells after Liver Transplantation**
Floris J M Roos, Rotterdam, Netherlands

#### O-135
**Significance of the Early Hepatic Stellate Cell (HSC) Activation on the Fibrotic Evolution of Liver Allografts: The Possible Benefit of Estrogen on this Process**
Mehmet Haberal, Ankara, Turkey

#### O-136
**The Assessment of the Safety of Using the Hepatitis B Surface Antigen-positive Donor for Liver Transplant**
Bo Zhang, Wuhan, China

#### O-137
Piyawat Komolmit, Bangkok, Thailand

### Concurrent Oral Abstract Session

**Meeting Hall 1**

#### Video

**Chairs:**
Martin Oliverius, Praha, Czech Republic
Kyung-Suk Suh, Seoul, Korea, Republic of

#### O-138
**Living Donor Liver Transplantation Using a Right Anterior Section of the Liver**
Kyung-Suk Suh, Seoul, Korea, Republic of

#### O-139
**A New Technique for Living Donor Liver Transplantation: Backtable Outflow Reconstruction and Bicaval Anastomosis with Veno-venous Bypass: Back to Basics**
Deniz Balci, Ankara, Turkey

#### O-140
**Pure Laparoscopic Living Donor Right Hepatectomy for Adult Liver Transplantation (4K, UHD)**
Ki-Hun Kim, Seoul, Korea, Republic of

#### O-141
**In-vivo Hepatectomy of Tumor Free Liver and Autotransplantation in Extensive Cholangiocarcinoma Invading All the Vascular Structures: Noble Way to R0 Resection**
Deok-Bog Moon, Seoul, Korea, Republic of

#### O-142
**Pure Right Lobe Donor Hepatectomy Using 3-D Laparoscopy for Adult-to-Adult Living Donor Liver Transplantation**
Hye Ryeon Choi, Daegu, Korea, Republic of

#### O-143
**Laparoscopic-assisted Living Donor Right Hepatectomy**
Adel Bozorgzadeh, Worcester, United States

#### O-144
**Introduction of extrahepatic Glissonian approach for living donor hepatectomy**
Taizo Hibi, Tokyo, Japan
O-145  Laparoscopic Approach for Living Donor to Paediatric Liver Transplant  18:40
Javier Briceno, Cordoba, Spain

O-146  Complicated Living Donor Liver Transplantation with Vascular Reconstruction by Using Cryopreserved Iliac Artery Allograft and Recipient's Greater Saphenous Vein  18:50
Zhe Yang, Hangzhou, China

Concurrent Oral Abstract Session
17:30 - 19:00  Meeting Hall 4

Pediatrics

Chairs:
Mohamed Rela, Chennai, India
Paolo Muiesan, Birmingham, United Kingdom

O-147  Chronic High Epstein-Bar Virus Loads in Pediatric Liver Transplant Recipients - Risk Factors and Long-term Outcomes  17:30
Hideya Kamei, Nagoya, Japan

O-148  Low Dose Steroid Regimen during Immediate Post Transplant Period in Pediatric Liver Transplant Recipients: A Comparative Study  17:40
Joseph Valamparampil, Chennai, India

O-149  Duct-to-Duct Biliary Reconstruction in Live Donor Pediatric Left Lobe Liver Transplantation  17:50
ZAZA Iakobadze, Izmir, Turkey

O-150  Liver Transplant for Primary Malignant Liver Tumors in Children  18:00
Miriam Cortes Cerisuelo, London, United Kingdom

O-151  Biliary Complications and Management in Paediatric Liver Transplantation: Outcomes from a High-volume Living Donor Centre  18:10
Rahul Roy, Gurugram, India

O-152  Risk Factors Associated with Hepatic Vein Outflow Obstruction in Pediatric Living Donor Liver Transplantation  18:20
Rodrigo Vincenzi, Sao Paulo, Brazil

O-153  When primary prophylaxis is beneficial to prevent gastrointestinal bleeding in biliary atresia with portal hypertension?  18:30
Roberta Angelico, Rome, Italy

O-154  Incidence, Risk Factors and Outcomes Related with Neurological Events after Liver Transplantation in Adult and Pediatric Recipients  18:40
Federico Pinero, Pilar, Argentina

YiChia Chan, Kaohsiung, Taiwan, Republic of China
### Scientific Programme

### Concurrent Oral Abstract Session  
17:30 - 19:00  
Meeting Hall 5

### Late Breaking Oral Abstracts

**Chairs:**  
Kim Olthoff, Philadelphia, United States  
Nancy Kwan Man, Hong Kong, Hong Kong

| LB O-2 | Lille Score Predicts Outcome in an ELAD Clinical Study of Severe Alcoholic Hepatitis (sAH)  
Lewis Teperman, Manhasset, United States | 17:30 |
| LB O-3 | Simultaneous Liver and Kidney Transplantation without the Use of Intraoperative Renal Replacement Therapy  
Dieter Adelmann, San Francisco, United States | 17:40 |
| LB O-4 | Alcoholic Liver Cirrhosis Is More Prone to Experience Postreperfusion Syndrome in Living Donor Liver Transplantation: Propensity Score Matched Analysis  
Hye-Mee Kwon, Seoul, Korea, Republic of | 17:50 |
| LB O-5 | The Association between Mucosal Associated Invariant T (MAIT) Cells and Liver Graft Quality  
Yasmeen Ghnewa, London, United Kingdom | 18:00 |
| LB O-6 | Impact of Treating vs. Not Treating HCV in Patients With Decompensated Cirrhosis - Analysis of Clinical Trials Database and Scientific Registry of Transplant Recipients (SRTR)  
Li Dong, Salt Lake City, United States | 18:10 |
| LB O-7 | Who Gets Better? Predictors of Clinically Meaningful Improvements in Liver Function among Patients with Decompensated Hepatitis C (HCV) Cirrhosis Receiving Direct-Acting Antiviral (DAA) Therapy  
Omar El Sherif, Dublin, Ireland | 18:20 |
| LB O-8 | Effect of Everolimus with Reduced Tacrolimus on Renal Function after Living-Donor Liver Transplantation (LDLT): 1-Year Results from a Randomized International Study  
Gary Levy, Toronto, Canada | 18:30 |
| LB O-9 | Liver Transplantation for Hepatocellular Carcinoma: Single Center Experience  
Kamil Yalçın Polat, Istanbul, Turkey | 18:40 |
| LB O-10 | Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks  
Georg Lurje, Aachen, Germany | 18:50 |
Scientific Programme

Saturday, 27 May 2017

Vanguard Sessions
06:30 - 08:00
Panorama Hall

Vanguard Video Lectures - Technical Challenges in Liver Transplantation

Chairs:
Hiroto Egawa, Tokyo, Japan
Jan Lerut, Bruxelles, Belgium

What can the senior teach to the junior surgeon? 06:30
Jan Lerut, Bruxelles, Belgium

Arterial Reconstruction 06:50
Deniz Balci, Ankara, Turkey
Alan Contreras, Mexico, Mexico

Hepatic Vein / Portal Vein Reconstruction 07:10
Taizo Hibi, Tokyo, Japan
Christian Toso, Geneva, Switzerland

Biliary Reconstruction 07:30
Prashant Bhangui, Medanta, India
Irene Scalera, Birmingham, United Kingdom

Discussion 07:50

Plenary Abstract Session
08:00 - 09:30
Congress Hall

Plenary Abstract Session 3

Chairs:
Christophe Duvoux, Créteil, France
Gianni Biancoffore, Pisa, Italy

O-156 5-year Experience in Human Extended DCD Liver Transplantation Treated by Hypothermic Oxygenated Perfusion (HOPE) before Implantation 08:00
Philipp Dutkowski, Zurich, Switzerland

O-157 Recurrence of Primary Sclerosing Cholangitis is Associated with Lower Survival after Liver Transplantation: An Analysis of the European Liver Transplant Registry Data Base 08:12
Thijmen Visseren, Rotterdam, Netherlands

O-158 U.S. Outcomes in Early Liver Transplantation for Alcoholic Hepatitis: Results from the American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) 08:24
Brian Lee, San Francisco, United States

O-159 Short- and Long-term Outcomes of Small for Size Liver Grafts in Right and Left Living Donor Liver Transplantation 08:36
Wong Hoi She, Hong Kong, Hong Kong
The 2017 Joint International Congress of ILTS, ELITA & LICAGE
May 24 - 27, 2017,
Prague, Czech Republic

Scientific Programme

O-160 A Comparison of Desensitization Protocols: Rituximab with/without Plasmapheresis in ABO-incompatible Living Donor Liver Transplantation
Seong Hoon Kim, Goyang, Korea, Republic of

O-161 Sirolimus Prolonged Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria; Outcome of a Multicenter Prospective Randomized Control Phase II Trial
Kwang-Woong Lee, Seoul, Korea, Republic of

O-162 Indentification of Hmox1 as a Novel Biomarker for Rejection and Prognosis Prediction after Liver Transplantation Based on ITRAQ Quantification
Junjun Jia, Hangzhou, China

State of the art lecture
09:30 - 10:00
Congress Hall

State-of-the-Art Lecture 3

Chairs:
Patrizia Burra, Padova, Italy

Liver inflammation and immunology: from basic science to liver transplantation
Frank Tacke, Aachen, Germany

Featured Symposium
10:00 - 11:30
Forum Hall

Liver transplantation for malignancies

Chairs:
Nancy Kwan Man, Hong Kong, Hong Kong
Kevin Kim, New Haven, United States

LT for HCC - modelling the criteria
Christian Toso, Geneva, Switzerland

Liver transplantation for biliary malignancies
Taizo Hibi, Tokyo, Japan

Neuroendocrine tumors and LT
Vincenzo Mazzaferro, Milan, Italy

LT for metastatic colorectal carcinoma
Rene Adam, Villejuif, France
Featured Symposium
10:00 - 11:30
Meeting Hall 1
HBV and HCV

Chairs:
Giacomo Germani, Padua, Italy

- **New ELITA guidelines for prevention of HBV recurrence**
  Christophe Duvoux, Créteil, France
  10:00

- **Update on management of HCV infection before and after LT: final ELITA recommendations**
  Luca Belli, Milan, Italy
  10:20

- **Remaining challenges of HCV in liver transplant recipients**
  Norah Terrault, San Francisco, United States
  10:40

- **HCV/HIV pre and posttransplant management**
  Jean-Charles Duclos-Vallee, Paris, France
  11:00

The best of ILTS
11:45 - 12:15
Meeting Hall 4
**The best of ILTS - Medical**

The Best of ILTS sessions will provide a summary of the novelties and promising pathways in terms of liver transplantation highlighted during the congress. By reviewing the Surgical/Anesthesiology and Medical aspects presented by faculty members, the congress will conclude on future issues, programs or projects that shall impact liver transplantation research, teaching, or program development.

- **The best of ILTS - Medical**
  Patrizia Burra, Padova, Italy
  11:45

The best of ILTS
11:45 - 12:15
Meeting Hall 5
**The best of ILTS - Surgical/Anesthesiology**

The Best of ILTS sessions will provide a summary of the novelties and promising pathways in terms of liver transplantation highlighted during the congress. By reviewing the Surgical/Anesthesiology and Medical aspects presented by faculty members, the congress will conclude on future issues, programs or projects that shall impact liver transplantation research, teaching, or program development.

- **The best of ILTS - Surgical/Anesthesiology**
  John Roberts, San Francisco, United States
  11:45